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The strategy to improve the lipophilicity of gemcitabine by conjugation with a lipid 
(e.g. docosahexaenoic acid (DHA) or stearoyl acid) allows to prevent the deamination of 
gemcitabine by cytidine deaminase, main cause of gemcitabine degradation in vivo. In 
addition, this strategy may confer gemcitabine a strong antitumor activity compared to 
parental drug. 4-(N)-docosahexaenoyl 2´, 2´-difluorodeoxycytidine (DHA-dFdC) is a 
novel compound with strong in vitro and in vivo antitumor activity in several cancer models 
(e.g. pancreatic, breast, leukemia, and lung cancer). However, the toxicity of DHA-dFdC 
has not been tested in an animal model. In this dissertation, a preclinical short-term toxicity 
study to evaluate the tolerability of DHA-dFdC was performed in healthy DBA/2 mice. 
DHA-dFdC showed a dose-dependent toxicity, affecting mainly the spleen. The repeat-
dose maximum tolerated dose (RD-MTD) of DHA-dFdC was 50 mg/kg. DHA-dFdC 
exhibits a strong efficacy at or below its RD-MTD in mouse models of pancreatic cancer 
or leukemia. Unfortunately, DHA-dFdC has two main issues, chemical instability and poor 
solubility in water. In this dissertation, a solid lipid nanoparticle (SLN) formulation of 
 viii 
DHA-dFdC was developed to improve its chemical stability and water solubility. The SLN 
formulation improves the apparent water solubility of DHA-dFdC by 2.6-fold, as compared 
to a previously developed DHA-dFdC in Tween 80-ethanol-water solution. The SLN 
formulation as a lyophilized powder also improves the chemical stability of DHA-dFdC. 
In addition, DHA-dFdC-SLNs showed stronger antitumor activity than DHA-dFdC in 
Tween-ethanol-water solution in a mouse model when given intravenously. Finally, this 
dissertation demonstrates in a mouse model that the absolute oral bioavailability of DHA-
dFdC in the DHA-dFdC-SLN formulation is 68%. It is concluded that the SLN formulation 
of the DHA-dFdC (i.e. DHA-dFdC-SLNs) improves the chemical stability of DHA-dFdC 
and increases its apparent water solubility, and the DHA-dFdC-SLNs can be administered 
intravenously or orally. 
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Chapter 1: Lipophilic Derivate of Gemcitabine as Strategy to Overcome Drug 
Resistance 
 
1.1  INTRODUCTION 
 
Cancer is a leading problem in public health around the world and it is the second cause of 
death in the United States (1). There are several options to treat cancer such as surgery, 
chemotherapy, radiation therapy, hormonal therapy, and targeted therapy. The adequate selection 
of treatment depends on many variables such as localization, grade, and stage of the disease (2). 
According to the American Cancer Society, the most common treatments for cancer are surgery, 
chemotherapy, and radiation. Most people receive a combination of treatments such as surgery 
plus chemotherapy and/or radiation therapy due to the spread of tumor cells to near areas and/or 
distant areas, avoiding a successful tumor elimination by surgery (2). In most cases it is not 
possible to use surgery, thus an alternative is the use of cytotoxic drugs to treat cancer. Most of the 
chemotherapeutic drugs have similar mechanisms of action, inducing cytotoxicity in cells 
undergoing rapid growth and proliferation, one of the hallmarks of cancer cells (3). For example, 
cisplatin is mainly used to treat bladder, ovarian, and testicular cancer (4). Another example is 




1.2  GEMCITABINE  
 
Gemcitabine is marketed as Gemzarâ by Eli Lilly and Company. Its empirical formula is 
C9H11F2N3O4 • HCl (gemcitabine HCl), with a molecular weight of 299.66 (g/mol) (5). It is 
soluble in water and is supplied for intravenous administration only (5). Gemcitabine was 
approved in 1996 by the Food and Drug Administration (FDA) as the first-line treatment for locally 
advanced and metastatic pancreatic cancer (6). Furthermore, it is administrated in combination 
with other drugs such as cisplatin, paclitaxel, or carboplatin to treat other cancers (i.e. locally 
advanced or metastatic non-small cell lung cancer, metastatic breast cancer, and advanced ovarian 
cancer; respectively) (7-9). Gemcitabine HCl (2´,2´-difluorodeoxycytidine HCl, dFdC) is a 
nucleoside analogue, which requires intracellular uptake, followed by sequential phosphorylation 
for its activation (6, 10). Because of its high hydrophilicity, it is not able to permeate plasma 
membranes by passive diffusion (6, 10, 11). For this reason, gemcitabine must be internalized into 
cells by specialized nucleoside transporters such as concentrative nucleoside transporter (hCNTs) 
and equilibrative nucleoside transporter (hENTs) (12, 13). However, kinetic studies demonstrated 
that gemcitabine is mainly incorporated by hENT1, which is critical for optimal response of 
gemcitabine (14). Indeed, its high expression was associated with in vitro chemosensitivity of 
gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells (15). Once into 
the cells, gemcitabine undergoes three sequential phosphorylations that allow its activation (6, 10). 
The rate-limiting step of activation is mediated by enzymes such as deoxycytidine kinase (dCK), 
which allows the first phosphorylation of gemcitabine, followed by two more rounds of 
phosphorylation to produce the active metabolites of gemcitabine (i.e. 2´,2´-difluoro-2´-
deoxycytidine triphosphate; dFdCTP) (6, 10). Therefore, this step is essential to the cytotoxic 
activity of gemcitabine (6, 10, 16). The most important mechanism of action of gemcitabine is 
inhibition of DNA synthesis (16). Gemcitabine is able to inhibit DNA synthesis because its 
triphosphate phosphorylated form (dFdCTP) is a competitive substrate of deoxycytidine 
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triphosphate, thus dFdCTP is incorporated into the DNA during replication, inhibiting the 
elongation chain (6, 10, 16). This process is known as "masked chain-termination" due to the non-
terminal position of dFdCTP, avoiding the detection and repair of DNA (6, 10, 16).  
In addition to its main function, gemcitabine has at least two more mechanisms of action: 
1) induction of apoptosis by caspase signaling, and 2) self-potentiation through inhibition of 
enzymes involved in deoxynucleotide metabolism, which allow high intracellular levels of the 
active metabolite, improving its mechanism of action (10, 17, 18).  
Gemcitabine is normally administrated as an intravenous infusion at a dose of 1000-1250 
mg/m2 given once weekly for a 3- or 4-week cycle (5). It has a short plasma circulation time (19). 
The elimination half-life depends on the gender and age of patients, as well as infusion duration 
(6). Longer infusion times are associated with higher toxicity (6). The most common toxicities 
associated with gemcitabine are myelosuppression, high levels of hepatoxicity, renal toxicity, 
thrombocytopenia, and anemia (19-21).  
 
 
1.3  GEMCITABINE CHALLENGES AND LIMITATIONS 
 
A major limitation of gemcitabine is the quick development of resistance by individual 
patients during treatment cycles. Gemcitabine resistance has been associated with the following 
factors: 
 
1.3.1  Inhibition of nucleoside transporters 
Gemcitabine is a hydrophilic drug with low membrane permeability, thus it requires a 
specialized transport system (i.e., nucleoside transporters) to be incorporated into the cells (11). A 
deficient influx of gemcitabine is associated with resistance to gemcitabine. Indeed, the absence 
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or low expression of hETN1, as well as hCNT3, are the most common causes of resistance in 
human breast and pancreatic cancer (12, 22). Thus, studies have proposed their evaluation as 
predictive factors for gemcitabine response (23, 24) 
 
1.3.2  Deficiency of dCK activity.  
As mentioned previously, gemcitabine is a prodrug that must undergo a series of 
phosphorylations to be active inside the cell, of which dCK is the rate-limiting enzyme responsible 
for the first phosphorylation of gemcitabine (6, 10, 25). A clinical study reported that high levels 
of dCK correlated with gemcitabine efficacy in pancreatic cancer, improving the overall survival 
in patients (26). On the other hand, regulation at the post-transcriptional level of dCK is associated 
with gemcitabine resistance in pancreatic cancer cells (6, 27). A study reported that overexpression 
of HuR in MiaPaCa2 (a pancreatic cancer cell line) correlated with a high sensitivity to 
gemcitabine (27). The same study also reported that the histology analysis of patients with 
pancreatic ductal adenocarcinoma showed a correlation between low cytoplasmic expression of 
HuR and poor survival due to resistance to gemcitabine compared to patients with high 
cytoplasmic expression of HuR, exhibiting a better prognosis (27) 
 
1.3.3  Overexpression of ribonucleotide reductase.  
Ribonucleotide reductase (RR) is a holoenzyme formed by two subunits RRM1 and RRM2 
(6, 10). The main function of this enzyme is to catalyze the conversion of ribonucleotide to 
deoxyribonucleoside triphosphate (dNTPs), which is modulated by the levels of its catalytic 
subunit M2 (RRM2) (6, 10, 16, 25, 28). Studies correlated the overexpression of RRM2 with 
resistance to gemcitabine in pancreatic, biliary, colon, and non-small cell lung cancer (10, 15, 28-
31). Indeed, in vitro and in vivo studies in pancreatic adenocarcinoma demonstrated that the 
suppression of RRM2 using RNA interference (siRNA) improves gemcitabine cytotoxicity, 
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suggesting the combination of gemcitabine and siRNA targeting RRM2 can induce strong 
suppression of tumor growth, increased apoptosis, and inhibition of metastasis (31).  
On the other hand, resistance to gemcitabine is not only associated with these three 
mechanisms, and other factors might also contribute to gemcitabine resistance. For example, 
deregulation of genes associated with apoptosis and survival (i.e., p53, Bcl-2, Bax, and Bak) are 
associated with gemcitabine resistance (32, 33). In addition, studies reported that NF-kB and also 
HIF-1a might play a role in resistance through inhibition of gemcitabine uptake and apoptosis (10, 
27, 32, 33). 
Another limitation associated with gemcitabine is a short plasma half-life due to the rapid 
and extensive inactivation by cytidine deaminase (CDA) to its inactive metabolite 2´, 2´-difluoro-
deoxyuridine (dFdU) (34). CDA is an enzyme ubiquitously expressed in the liver and blood, thus 
inactivation of gemcitabine mainly occurs in the liver and to a lesser extent in the blood, followed 
by rapid excretion in the urine (6, 34).  
Considering these limitations of gemcitabine, new strategies to improve the transport and 
avoid its inactivation are necessary. Therefore, the focus of the next section is to discuss some 
examples of chemical modification at 4-(N)-positions to overcome the mechanism of gemcitabine 
resistance by protection from deamination. 
 
 
1.4  CHEMICAL MODIFICATION OF GEMCITABINE AT 4-(N)- POSITION 
 
Drug modifications have long been used in different anticancer drugs to overcome the 
limitations of the parent drug such as rapid clearance, enzymatic degradation, poor uptake, 
pharmacokinetic limitations, and so on. In the case of gemcitabine, chemical modification at the 
4-(N)-position confers special protection against deamination, improving its bioavailability (6). 
The activation of gemcitabine occurs by the hydrolysis of the amide bond, which has a slower rate 
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due to its higher stability, conferring extended blood circulation (35) . Some examples of 4-(N)-
modifications of gemcitabine are: 
 
1.4.1  PEG-Gemcitabine. 
This prodrug is formed by the conjugation of gemcitabine with poly(ethylene glycol) to 
improve the drug plasma half-life due to low clearance by the kidneys (36). In addition, the 
prevention of degradation by cytidine-deaminase increases significantly the bioavailability of 
PEG-gemcitabine over gemcitabine (36). Similar results were reported when Ara-C, structurally 
similar to gemcitabine, was conjugated at 4-(N)-position with PEG, improving its stability and 
pharmacokinetic parameters (37).  
 
1.4.2  LY2334737 
Oral administration of a prodrug of gemcitabine is achievable rather than gemcitabine (6, 
38). Oral administration of gemcitabine is not feasible due to the abundant concentration of CDA 
in blood, liver, and gut, which metabolizes gemcitabine to dFdU (6, 34, 38). In fact, gemcitabine 
has a low systemic exposure due to extensive first-pass metabolism to dFdU, showing a moderate 
gastrointestinal toxicity when orally administrated to patients with refractory tumors (38). 
Therefore, amine group protection by prodrug formation can hinder the deamination site, 
improving the oral bioavailability (6). For instance, LY2334737 was developed by covalently 
linking valproic acid (VPA) via an amide bond at the 4-(N)-position, reporting a good chemical 
and enzymatic stability (39). A preclinical study demonstrated the intact absorption of LY2334737 
by the intestinal epithelium, avoiding first-pass metabolism and allowing its intact delivery into 
the systemic circulation (40). Moreover, LY2334737 has a slow hydrolysis, leading to sustained 
in vivo release of gemcitabine (40). This study also showed that carboxylesterase 2 (CES2) was 
responsible for the in vitro hydrolysis of LY2334747 (40). A phase I study in Japanese patients 
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with advance solid tumors showed a good tolerability at doses up to 30 mg/day while at the 40 
mg/day dose some patients reported dose-limiting toxicities (DLT) such as hepatic toxicity, 
thrombocytopenia, and disseminated intravascular coagulation (41). LY2334747 was also used in 
combination with erlotinib in a phase I study, in which the maximum tolerated dose (MTD) was 
40 mg with or without daily administration of 100 mg of erlotinib in European patients with 
advanced solid tumors (42). The most common DLT for LY2334737 monotherapy were fatigue 
and high levels of transaminase, while for combination therapy the most common adverse events 
were fatigue, nausea, vomiting, and elevated transaminase levels (42).  
 
1.4.3  Lipophilic prodrugs 
Lipophilic derivatives of gemcitabine are another strategy used to improve blood stability 
and increase gemcitabine cytotoxicity (6). This strategy consists of conjugating gemcitabine with 
lipids such as fatty acids or phospholipids to increase its lipophilicity, as well as modify other 
properties of gemcitabine (35). An amide bond can be formed through the covalent conjugation of 
the fatty acids’ carboxylic acid end position to the amine group of gemcitabine, while an ester 
bond may be formed by the reaction between the hydroxyl group of gemcitabine and the carboxylic 
acid group of phospholipids (6, 35). Some examples of fatty acids conjugated with gemcitabine 
will be discussed next. 
As previously mentioned, a lipophilic derivative of gemcitabine can be formed by covalent 
conjugation of fatty acids, such as squalene acid (SQ), stearic acid (SA), or docosahexaenoic acid 
(DHA) (43-46). For example, squalenoyl gemcitabine (SQdFdC) is formed by the conjugation of 
squalene with gemcitabine and allows the formation of amphiphilic molecules that can self-
organize in water as nanoassemblies (SQdFdC NA) of 100-300 nm (43). In vitro studies showed 
a higher cytotoxicity of SQdFdC NA, rather than gemcitabine, against MCF-7 (human breast 
carcinoma) and KB3-1 (human nasopharyngeal carcinoma) cells, and also a strong cytotoxicity 
against L1210k cells, a resistant phenotype of L1210wt cell with downregulation of deoxycytidine 
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kinase (dCK) (43, 47). Intravenous administration of SQdFdC NA exhibited strong anticancer 
activity against leukemia-bearing mice and solid P388 tumors, increasing survival and limiting 
tumor growth, respectively (48). In fact, SQdFdC NA increased the apoptosis level of cancer cell 
lines compared to gemcitabine (47). Moreover, a preclinical toxicity study showed a dose-
dependent toxicity independent of the route of administration (i.e. intravenous or subcutaneous), 
reporting a similar toxicological profile to gemcitabine at equitoxic doses, while a potent 
anticancer activity was reported in a leukemia model with 75% long-term survivors (49). This 
higher efficacy of SQdFdC NA is due to the favorable modification of pharmacokinetic 
parameters, as well as a selective organ distribution (50). For instance, half-life and mean residence 
time of SQdFdC NA were greater than gemcitabine administrated as free drug (~3.9-fold and ~7.5-
fold, respectively) (50). In addition, the biodistribution study showed longer body retention of 
SQdFdC compared to dFdC, as well as higher accumulation of SQdFdC in spleen and liver, the 
main organs responsible for metastasis in leukemia and other cancers (50). In addition, the 
anticancer efficacy of SQdFdC NA after oral administration to rats bearing large granular 
lymphocytic (LGL) leukemia was also investigated (43).  SQdFdC NA exhibited superior 
anticancer activity as compared to gemcitabine, increasing the life span of rats and the number of 
long-term survivors (43). The factors that could explain this superior efficacy of SQdFdC NA are: 
1) resistance to deamination, 2) favorable pharmacokinetics, and 3) increased accumulation in the 
lymphoid organs (51). Therefore, these data support the candidacy of SQdFdC NA as alternative 
therapy to leukemia by oral or parental route (43, 51).   
4-(N)-stearoyl-gemcitabine (i.e. GemC18) and 4-(N)-lauroyl-gemcitabine (i.e. GemC12) 
are other examples of lipophilic gemcitabine prodrugs, which showed higher cytotoxicity activity 
against HT-29 colon adenocarcinoma and KB nasopharyngeal carcinoma compared to 
gemcitabine (44). In addition, GemC18, as well as GemC12, showed a slow metabolism in plasma, 
with 90 % of the intact prodrug recovered after 8 h while no more than 40% of unmodified 
gemcitabine was recovered after 8 h (44). GemC18 was encapsulated into liposomes to improve 
the in vitro and in vivo stability (44). Its encapsulation enhanced the passive diffusion across the 
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cell membrane, increasing the prodrug cytotoxicity in comparison with gemcitabine, which is not 
permeable to the cell membrane as previously mentioned (11, 13, 44, 52). Therefore, GemC18-
liposome allows protection against deamination, increasing the plasma half-life of the drug, which 
increases the antitumor potency due to its higher tumor concentration (52).  
Another example of a lipophilic derivative of gemcitabine is 4-(N)-docosahexaenoyl 2′, 2′-
difluorodeoxycytidine (DHA-dFdC), which was synthetized by conjugation of docahexaenoic acid 
(DHA), an omega-3 polyunsaturated fatty acid (PUFA), to dFdC at the 4-(N)-position. This novel 
compound showed promising results such as potent cytotoxicity against several cancer cell lines 
(e.g. leukemia, renal, pancreatic, breast cancer cells) and strong antitumor activity against MCF-7 
tumor-bearing nude mice, Panc-1 pancreatic tumors, and leukemia bearing mice as compared to 
gemcitabine (45, 46). In fact, DHA-dFdC was significantly more cytotoxic than dFdC in BxPC-3 
cells (i.e. pancreatic cancer cells) with an IC50 of 100,000-fold smaller than dFdC (46). These data 
show the potency of DHA-dFdC at significant lower dose than dFdC that might help to reduce the 
toxic effect of dFd on normal cells (45). Therefore, in vivo studies showed that DHA-dFdC 
significantly inhibited Panc-1-luc tumor growth while equimolar dose of dFdC did not 
significantly inhibit the tumor growth (46). These data demonstrated the strong antitumor activity 
of DHA-dFdC over dFdC due to Panc-1 tumor cells are known to be resistance to dFdC, thus 
DHA-dFdC might a new potent drug derivate from dFdC that migh a potential candidate to treat 
pancreatic cancer resistant to dFdC (46).  Moreover, mice genetically engineered to spontaneously 
develop pancreatic ductal adenocarcinoma treated with DHA-dFdC showed greater survival than 
untreated mice (46). The potent antitumor activity of DHA-dFdC might be related to its DHA 
portion, which can increase drug transportation across tumor cell membranes (45). Furthermore, 
studies relate the use of natural fatty acids by tumor cells as a source of energy and biochemical 
precursor supply in several processes (53-55). In fact, various drugs (e.g. paclitaxel, doxorubicin, 
10-hydroxycamptothecin) have been conjugated with DHA to improve their tumor targeting, 
leading to greater drug concentration in the tumor and, as a consequence, reducing toxicity in 
normal tissues (35, 54, 56). For instance, DHA-paclitaxel (or Taxoprexin) showed preferential 
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uptake by tumor compared to normal tissue at preclinical levels (35, 56). DHA conjugated to 
paclitaxel changes the pharmacokinetic profile of paclitaxel, increasing the concentration and 
retention of DHA-paclitaxel that slowly might cleave and convert into paclitaxel (56). Similar 
results were found in phase I clinical trials where DHA-paclitaxel showed higher half-life and slow 
clearance compared to paclitaxel (57). Therefore, the tumor targeting strategy might explain the 
greater potency of DHA-dFdC in several tumor models, but more studies related with the 
formulation of DHA-dFdC are necessary due to its chemical instability in solution and poor water 
solubility, as both properties might affect its performance in clinical studies. Due to the promising 
results of DHA-dFdC, the improvement of its formulation is one of the main purposes of this 
dissertation and will be discussed later. 
In terms of toxicity, DHA-dFdC was well-tolerated at preclinical levels but this study will 
be discussed in detail in the next chapter of this dissertation.  
 
1.4.4  Advantages of lipophilic prodrug of gemcitabine 
As discussed in the previous section, the lipophilic prodrugs of gemcitabine offer several 
advantages over gemcitabine. For instance: 
1.4.4.1 Lipophilic prodrugs can improve the oral bioavailability of gemcitabine.  
Lipid-gemcitabine conjugation at 4-(N)-position protects from extensive deamination in 
the liver and gut, as previously mentioned. An example of an oral gemcitabine prodrug is SQdFdC 
NA , which showed strong antitumor activity against a leukemia rat model at preclinical levels 
(51). In general, lipid-conjugation increased the lipophilicity of the parental drug, which can 
improve the membrane cell interaction (6, 35, 44). In addition, lipid-drugs can use the lymphatic 
system, avoiding the first pass-metabolism, and contribute enhanced oral bioavailability (35, 43, 
58). However, the lymphatic transport will depend on the lipophilicity of the drug. Thus, a lipid-
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drug with logP higher than 5 will be transferred directly into the lymphatic system while a lipid-
drug with logP lower than 5 will be transported to the blood circulation (35).  
 
1.4.4.2 Improve tumor targeting and as a consequence reduce toxicity.  
Most of the examples previously discussed showed higher tumor targeting. For example, 
biodistribution of DHA-dFdC showed higher concentrations in mouse pancreas compared to other 
organs (i.e. liver, kidney, spleen, lung, and heart), one hour after intravenous administration (46). 
Furthermore, DHA-dFdC inhibited tumor growth in nude mice with orthotopic pancreatic tumors, 
as well as improved survival in transgenic mice that spontaneously developed pancreatic tumors 
(46). This evidence suggests tumor targeting of DHA-dFdC against pancreatic cancer. 
Lipophilic prodrugs of gemcitabine reduce drug toxicity due to their strong tumor targeting. 
In addition, the prodrug is inactive until the hydrolysis of the amide bond occurs in the tumor cells, 
minimizing the exposure of normal organs to the active drug. Cathepsins are lysosomal enzymes 
overexpressed in cancer cells, which are mainly responsible for prodrug activation by cleavage of 
amidic-linkage (59). Cathepsin B (a cysteine protease) and cathepsin D (an aspartic protease) are 
the main enzymes responsible for SQdFdC NA and GemC18 hydrolysis, converting the prodrug 
into the active gemcitabine (43, 44).  
 
1.4.4.3 Lipophilic prodrugs of gemcitabine can be encapsulated into nanoparticles.  
Lipophilic drugs have greater drug loading into carriers that contain lipophilic components, 
exhibiting minimal drug leakage (35). The most common carriers for lipophilic drugs are 
liposomes, polymeric micelles, polymeric nanoparticles, and solid lipid nanoparticles. SQdFdC 
NA, as well as GemC18, have been incorporated into delivery carriers, improving their antitumor 
activity and their pharmacokinetic parameters (6, 35). Indeed, the encapsulation of GemC18 into 
solid lipid nanoparticles allows its oral administration, overcoming detrimental effects of the 
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formulation (60). Due to its low solubility, GemC18 was dissolved in oil for oral administration in 
mice, which resulted in significant weight loss and signs of distress (60). The adverse effects were 
attributed to the GemC18-oil formulation, since gavaging with oil alone was well-tolerated by 
mice (60).  
As mentioned before, the poor water solubility of lipophilic drugs (e.g. GemC18 and dFdC-
DHA) is the main problem for drug formulation, restricting their administration. Furthermore, the 
formulation (i.e. lipophilic prodrug in the vehicle) might induce side effects, like GemC18 in oil. 
Additionally, the lipophilic prodrug might exhibit chemical instability, like dFdC-DHA. Thus, the 
encapsulation of these lipophilic prodrugs into nanoparticles has emerged as an alternative 
technology to overcome these problems. Furthermore, nanoparticles may improve their antitumor 
activity as well as their pharmacokinetic parameters.  
 
 
1.5  NANOTECHNOLOGY AS A TOOL TO IMPROVE GEMCITABINE LIPOPHILIC DERIVATIVES 
PROPERTIES 
 
Nanotechnology may improve the therapeutic effectiveness and safety profile of 
chemotherapeutics, such as lipophilic derivatives of gemcitabine. Nanoparticles provide extra 
protection from deamination, thus prolonging the drug blood circulation (6, 35, 61-63). In addition, 
the incorporation of hydrophilic polymers (e.g. polaxamers or PEG) into the shell increases the 
drug half-life, reducing aggregation and immunogenicity (6, 63, 64). Cancer cells are able to 
develop drug resistance that restricts the therapeutic efficacy of chemotherapeutic drugs. The use 
of nanoparticles as a carrier delivery system might overcome drug resistance and also increase the 
drug cytotoxicity (3, 63). In addition, coating nanoparticles with specific ligands (e.g. folic acid, 
transferrin, EGF, lectins, VEGF, VCAM-1, and so on) that are overexpressed on cancer cells can 
improve their cell uptake, reducing the drug toxicity and increasing its antitumor activity (6, 35, 
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63, 65). In this section, some examples of lipophilic derivates of gemcitabine loaded into 
nanocarriers and their main advantages are discussed.  
 
1.5.1  Liposomes 
Liposomes are small spherical vesicles that are mainly composed by biocompatible and 
biodegradable phospholipids that can form one or more bilayers, mimicking the cell membrane 
structure (66). Liposome structure is organized as an enclosed compartment on which phospholipid 
bilayers divide an aqueous medium from another. This structure allows the entrapment of 
hydrophilic drugs in the aqueous compartment while lipophilic drugs are incorporated in the lipid 
membrane (35). Some examples of liposomes approved by the FDA are DoxilÒ and MarqiboÒ, 
in 1995 and 2012, respectively (67). DoxilÒ is a doxorubicin hydrochloride (HCl) liposome 
injection used to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other 
solid tumors (67). MarqiboÒ is a vincristine sulfate liposome injection used to treat adult 
Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) (67).  
Liposomes present various advantages such as: 1) improved efficacy and therapeutic index 
of drugs, 2) protection of the loaded drug from inactivation following intravenous administration, 
3) use of biocompatible and biodegradable materials, 4) improved safety due to non-toxicity, 5) 
flexibility to combine with site-specific ligands to achieve active targeting, 6) increased 
concentration of the encapsulated drug in the tumor, and 7) low risk of nonspecific toxicity (61, 
66, 67). However, liposomes also present various disadvantages such as 1) low solubility, 2) short 
half-life, 3) leakage and fusion of encapsulated drugs, and 4) low stability, limiting their use in 
cancer therapy (61, 67). A good example of these limitations is gemcitabine-loaded liposomes 
(66). Due to its hydrophilic nature, gemcitabine is completely loaded into the aqueous 
compartment of liposomes and rapidly diffuses out of liposomes (68). To overcome this 
disadvantage, the use of lipophilic prodrugs of gemcitabine have emerged as an alternative to 
encapsulate into liposomes (44, 66). For example, 4-(N)-acyl derivative prodrug of gemcitabine 
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loaded in liposomes showed a better stability and higher encapsulation efficiency (EE) than 
gemcitabine-loaded liposomes (44). The EE is mainly affected by the length of saturated 4-(N)-
acyl chain, the nature of phospholipids, and the presence of cholesterol (44). Indeed, 4-(N)-
stearoyl-gemcitabine (GemC18) and 4-(N)-lauroyl-gemcitabine (GemC12) in liposomes 
composed by DSPC/DSPG 9:1 showed greater EE, at ~98% and ~94%, respectively (44). 
Furthermore, GemC18 liposomes exhibited better in vitro stability on storage than GemC12 
liposomes (44). Moreover, the encapsulation of GemC18 into liposomes provides an additional 
protection against deamination, improving its pharmacokinetic behavior (6, 44). For example, 
GemC18 liposomes exhibited higher half-life and AUC than gemcitabine when intravenously 
administered (3.5-fold and 50-fold, respectively), resulting in strong antitumor activity due to its 
higher tumor accumulation (44, 52).  
 
1.5.2  Polymeric micelles  
Polymeric micelles are small sized (< 200 nm) drug delivery systems composed of 
amphiphilic polymers that self-assemble into core-shell structured nanocarriers, which include a 
hydrophilic shell and a hydrophobic core (35, 69). This core-shell structure allows the 
encapsulation of hydrophobic drugs into the core by no covalent interactions (35). In addition, the 
hydrophilic shell can increase their circulation in the blood and sterically stabilize, preventing 
aggregation and protein adhesion (69, 70). Polymeric micelles might contain a broad spectrum of 
polymers, but the use of biodegradable and biocompatible polymers is required to ensure their 
safety as nanocarriers (70-72). 
One of the most critical requirement of micelles is good stability of drug loading to achieve 
an optimal tumor targeting (69). Lipophilic prodrug strategy is a promising alternative to improve 
drug loading into micelles, minimizing their drug release before reaching the tumor site (35, 69). 
For example, doxorubicin-palmitic acid (DOX-PA) was synthesized by conjugation of 
doxorubicin with palmitic acid through an acid pH-responsive hydrazone linker, which is stable at 
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neutral pH (69). DOX-PA loaded into DSPE-PEG showed a higher encapsulation efficiency (i.e. 
~ 100 %) and good stability (69). In addition, this formulation did not show drug expulsion after 
3 weeks of storage at 4°C (69). Therefore, lipid conjugation with DOX might improve its 
lipophilicity, improving its encapsulation efficiency (35). Moreover, the lipid portion of DOX-PA 
can enhance compatibility and interaction of DOX with the lipid core of DSPE-PEG micelle, 
inducing a higher stability of the drug loaded into the micelles (69). 
GemC18 is another example of a lipophilic prodrug loaded into micelles. GemC18 loaded 
into poly(ethylene glycol)-poly(D,L-lactide) (PEG-PLA) polymeric micelles exhibited a higher 
encapsulation, sustained release, and higher cytotoxicity compared to Gem and GemC18 solution 
against pancreatic cancer cell lines ( i.e. Panc-1, and AsPC-1 cells) (72). In vivo and in vitro 
GemC18 loaded into DSPE-PEG/tocopherol-PEG 100-succinate (TPGS) mixed micelles 
increased drug stability by protection against deamination, improving its pharmacokinetic profile 
(73). Indeed, after intravenous administration, GemC18-loaded DSPE-PEG/TPGS micelles 
showed 2-5-fold higher plasma concentration, 3-fold greater systemic exposure (AUC), and lower 
volume of distribution at the steady state (Vd,ss), suggesting slow release of GemC18 from the 
mixed micelles and increased circulation in the bloodstream (73). Furthermore, this formulation 
exhibited stronger antitumor activity than free drug against BxPC-3 tumor bearing mice (73).  
Acid-sensitive micelles is another approach to improve tumor targeting due to the acidic 
extracellular environment of the tumor tissue (pH ~6.8), compared with surrounding normal 
tissues (74). GemC18 loaded into pH-sensitive micelles were prepared by conjugation of PEG 
with a hydrophobic stearic acid derivate (C18) using an acid-sensitive hydrazone bond (PHC) (75). 
GemC18 carried by pH-sensitive micelles exhibited stronger in vivo antitumor activity compared 
to acid-insensitive micelles, gemcitabine HCL in solution, or GemC18 in solution against B16-
F10 melanoma-bearing mice (75). The lysosomal delivery of GemC18 by micelles confers various 
advantages such as longer blood circulation time, higher tumor accumulation, and protection from 
deamination, and as consequence increased antitumor activity of GemC18 (75). In fact, this 
formulation was able to overcome the tumor cells resistant to gemcitabine through inhibition of 
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the expression of RRM1 and increased the level of gemcitabine triphosphate (dFdCTP), which can 
explain the greater antitumor activity of this formulation (76). 
 
1.5.3  Polymeric nanoparticles 
Polymeric nanoparticles (PNPs) are biodegradable colloidal systems, exhibiting various 
alternatives as drugs carriers, such as: 1) absorbed in the polymeric matrix, 2) entrapped into the 
core surrounded by the polymeric matrix, or 3) conjugated either within or onto their surface (71, 
77). The main attributes for selection of the correct polymer are easy manufacturing, 
biodegradability, and extended drug release (71, 77). As with polymeric micelles, the shell 
function provides drug protection against enzymatic degradation. For instance, polyvinyl alcohol 
(PVA), polyethylene glycol (PEG), polylactic acid (PLA), poly(D,L- lactide-co-glycolic) acid 
(PLGA), monomethoxy poly-(ethylene glycol) (mPEG), polysorbate and Vitamin E D-alpha 
tocopheryl polyethylene glycol 1000 succinate (TPGS) are common polymers used in PNPs (71).  
PNPs also have been used as carriers for lipophilic prodrugs such as UDCA-AZT (a 
prodrug of zidovudine), GemC18, and SN-38 (an inhibitor of topoisomerase I) (78-81). PLGA 
and/or PEG are common polymers used to deliver lipophilic prodrugs in PNPs (6, 71, 79, 81). For 
example, PEG-PLGA NPs were used to deliver SN-38, which is very unstable and incompatible 
with various carriers, and exhibited greater stability, longer half-life, and promoted its tumor 
accumulation (78). This formulation takes advantage of the leaking tumor structure, increasing the 
drug accumulation through the enhanced permeability and retention effect (EPR). On the other 
hand, active targeting also has been used to improve the antitumor effect of PNPs. For example, 
several studies demonstrated the over-expression of the epidermal growth factor receptor (EGFR) 
in various human tumor cell lines such as head and neck cancer cells, breast cancer cells, pancreatic 
cancer cells, and so on (82, 83). Thus, its ligand (EGF) was used to target GemC18-NPs (EGF-
GemC18-NPs), showing stronger anti-tumor activity than GemC18-NPs (65).  
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1.5.4  Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are colloidal systems with a submicron range of diameter 
(50-1000 nm), which offer an alternative to traditional colloidal carriers, such as emulsions, 
liposomes, and polymeric micro- and nanoparticles (84, 85). SLNs structure contain a solid lipid 
core surrounded by a monolayer phospholipid shell (86). The lipophilic portion of the phospholipid 
is embedded in the lipid matrix (86). SLNs are prepared using lipids solid at room and body 
temperature (i.e. mono-, di-, and triglycerides, fatty acids, waxes and steroids) stabilized by 
surfactant(s) (i.e. phospholipids, Poloxamers, and Polysorbates) (62, 86). SLNs can encapsulate 
both lipophilic and hydrophilic drugs, thus the drug encapsulation will depend on three factors: 1) 
type of solid lipid selected, 2) method of preparation, and 3) polymorphic change in lipid crystal 
(86, 87). This formulation exhibits several advantages such as improved drug stability, easy 
sterilization, enhanced bioavailability, chemical protection of labile drugs, easier and cheaper 
manufacturing than PNPs, low toxicity, and controlled release (62, 84, 86, 88). Furthermore, most 
of the lipids and surfactants used to prepare SLNs are approved by the FDA and have GRAS 
(Generally Recognized As Safe) status (62). In addition, SLNs manufacturing allows their 
administration through different routes such as parental (i.e. intravenously, intramuscularly or 
subcutaneously), oral, rectal, ophthalmic, and topical (62, 89-95). 
SLNs have been proposed as carriers for lipophilic prodrugs due to their efficient 
encapsulation into the lipid core, improved drug stability by protection from enzymatic 
degradation, as well as delayed drug release (62, 88). In addition, tissue targeting is an additional 
benefit conferred by SLNs (3). For instance, 3’, 5’-dioctanoyl-5-fluoro-2’-deoxyuridine (DO-
FUdR), a lipophilic prodrug derived from 5-fluoro-2’-deoxyuridine (FUdR), was incorporated into 
SLNs, showing in vitro extended drug release and in vivo specific brain targeting after intravenous 
administration (96). In fact, AUC and half-life values of DO-FUdR-SLN were higher in the brain 
compared to DO-FDUdR (~2.06-fold and ~1.49-fold, respectively) (96). Moreover, SLNs can 
increase drug cytotoxicity due to their faster internalization into cells, followed by the drug’s 
release from SLNs inside of the cells (97). For example, SN38 was incorporated into SLNs based 
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on Compritol 888 ATO, exhibiting higher cytotoxicity against breast cancer cell lines (i.e. MCF7) 
compared to SN38 in solution (98). In addition, other SLN formulations of SN38 based on 
Compritol 888 ATO and Precirol showed greater in vivo and in vitro antitumor activity against C-
26 tumor bearing mice (i.e. colorectal carcinoma tumor) compared to the commercially available 
parent drug (i.e. irinotecan) (99). Indeed, SLN-SN38 improved mice survival at lower doses (i.e. 
20 mg/kg) than irinotecan MTD (i.e. 50 mg/kg), decreasing the toxicity associated with higher 
concentrations (99).  
SLNs also can be orally administered as previously described (90, 91). Oral administration 
is considered one of the most traditional routes of drug delivery, offering various advantages such 
as convenient, comfortable, painlessness, easy self-administration, high patient compliance, and 
low cost (86). However, this route has several limitations related to physicochemical properties of 
the drug such as poor solubility and chemical instability in the gastrointestinal tract (GI), low 
permeability, and rapid metabolism, which decrease the oral bioavailability (58, 86). SLNs have 
emerged as alternative drug delivery systems for oral administration due to their ability to improve 
the oral bioavailability through their controlled release, protection against enzymatic degradation 
in the GI tract, as well as site-specific drug delivery (86). In fact, SLNs have been used successfully 
as oral delivery systems to improve the oral bioavailability of lipophilic drugs such as docetaxel, 
paclitaxel, cyclosporine A, vinpocetine, lopinavir, quercetin, and so on (86, 100-104). 
Furthermore, the nature of the shell coating on SLNs might allow their direct absorption by the 
lymphatic system, avoiding the first past metabolism (86). For example, wheat germ agglutinin 
(WGA)-coated SLNs improved the oral bioavailability of paclitaxel due to WGA linked N-acetyl-
D-glucosamine and sialic acid localized on intestinal surface cells (101, 105). Moreover, SLNs 
coated with D-a-tocopheryl poly(ethylene glycol) succinate (TPGS) enhanced the intestinal 
absorption and bioavailability of docetaxel, due to its potent Pgp-inhibiting activity (100). Another 
example of coating modification are PEGylated SLNs, in which PEG acts as a potent mucus-
penetrating agent, overcoming the mucus barrier and improving drug transport across the 
gastrointestinal epithelia (106).  
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GemC18-SLNs is an example of lipophilic prodrug loaded into SLNs for oral 
administration. Previously, GemC18-SLNs, prepared with soy lecithin, glycerol monostearate 
(GMS), Tween 20, and DSPE-PEG (2000), showed stronger antitumor activity against mouse 
models of lung and pancreatic cancer than equimolar doses of free gemcitabine given by 
intravenous administration (107). Similarly, oral administration of GemC18-SLNs exhibited a 
higher efficacy against pre-established lung tumors (i.e. mouse TC-1 or LCC lung cancer cells) 
compared to free gemcitabine HCL or GemC18 alone at an equimolar dose (60). Moreover, 
GemC18-SLNs showed a higher absolute oral bioavailability than that of gemcitabine (~70 % 
based on AUC0-24h), which might help to explain the GemC18-SLNs ability to inhibit tumor 
growth, as well as increase mice survival in pre-established lung tumor models (60). 
Immunohistostaining of LCC tumor suggested that the mechanism of action of oral GemC18-
SLNs was inhibition of tumor proliferation and angiogenesis, while increasing cell apoptosis (60). 
Nanoparticles can reach the tumor through passive targeting, in which the defective and 
leaky vasculature tumor architecture allows their passive diffusion into cancer cells (63). 
Furthermore, the inefficient lymphatic drainage of the tumor leads to nanoparticles’ extravasation 
and retention in the interstitium of tumors, a phenomenon known as ²enhanced permeability and 
retention² (EPR) (63, 108). However, passive targeting is determined by the tumor 
microvasculature (e.g. degree of tumor vasculature and angiogenesis), and nanoparticle properties 
(e.g. size, shape, and surface charge) (63). The ideal nanocarrier has at least three characteristics: 
1) a size between 10-100 nm to avoid filtration by the kidney (> 10 nm) and capture by the liver 
(< 100 nm) (63); 2) a neutral or anionic charge to avoid renal elimination; and 3) a long circulation 
time to evade the reticule-endothelial system (63). Thus, SLNs that have these properties might 
take advantage of the EPR to be incorporated into the tumor cells.  
Considering this evidence, SLNs were selected as a carrier for a DHA-dFdC, a lipophilic 
gemcitabine derivate, to improve its solubility, enhance its chemical stability, modify its 
pharmacokinetic parameters, as well as improve its antitumor activity. 
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1.6  CONCLUSION 
 
Lipophilic gemcitabine is a promising strategy to overcome the mechanisms of resistance 
to gemcitabine. This strategy allows for the modification of the pharmacokinetic profile and 
reduction in the systemic toxicity. Lipophilic derivatives of gemcitabine, such as GemC18, 
SQdFdC NA, and DHA-dFdC, showed a favorable pharmacokinetic profile, low toxicity, and 
strong antitumor activity compared to gemcitabine. Moreover, tumor targeting is a property 
exhibited by lipid-drug conjugates such as lipophilic derivatives of gemcitabine. The pancreatic 
tumor targeting exhibited by DHA-dFdC explained its potent efficacy against pancreatic cancer 
compared to gemcitabine. Thus, the tumor targeting of DHA-dFdC can be exploited to treat 
pancreatic cancer. However, the strong antitumor activity exhibited by lipophilic derivatives of 
gemcitabine, like DHA-dFdC, was obtained at the expense of their solubility. The encapsulation 
of lipophilic derivatives of gemcitabine into nanoparticles can improve their solubility. Due to its 
lipophilic nature, SLNs might the best candidate as a drug delivery system to encapsulate lipophilic 
derivatives of gemcitabine, offering better encapsulation into the lipid core and sustained released, 
increasing their therapeutic effects with minimal toxicity, and protecting from chemical and 
enzymatic degradation. Furthermore, SLNs offer the possibility to exploit the oral route of 
administration, preferred by patients, physicians, and the health insurance industry due to 
convenience and lower costs. Thus, SLNs are a potential carrier for lipophilic drugs with low 
solubility and chemical instability such as DHA-dFdC. 
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Chapter 2: Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-
Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC)1 
 
2.1 ABSTRACT  
Purpose: This study was designed to test the short-term toxicity of DHA-dFdC in a mouse model 
and its efficacy in a mouse model of leukemia at or below its repeat-dose maximum tolerated dose 
(RD-MTD). 
Method: A repeat-dose dose-ranging toxicity study was designed to determine the tolerability of 
DHA-dFdC when administered to DBA/2 mice by intravenous (i.v.) injection on a repeat-dose 
schedule (i.e. injections on days 0, 3, 7, 10, and 13). In order to determine the effect of a lethal 
dose of DHA-dFdC, mice were injected i.v. with three doses of DHA-dFdC at 100 mg/kg on days 
0, 3, and 5 (i.e. a lethal-RD). The body weight of mice was recorded two or three times a week. At 
the end of the study, major organs (i.e. heart, liver, spleen, kidney, lung, and pancreas) of mice 
that received the lethal-RD or RD-MTD were weighed, and blood samples were collected for 
analyses. Finally, DHA-dFdC was i.v. injected into DBA/2 mice with syngeneic L1210 mouse 
leukemia cells to evaluate its efficacy at or below RD-MTD. 
Results: The RD-MTD of DHA-dFdC is 50 mg/kg. At 100 mg/kg, a lethal-RD, DHA-dFdC 
decreases the weights of mouse spleen and liver and significantly affected certain blood parameters 
(i.e. white blood cells, lymphocytes, eosinophils, and neutrophil segmented). At or below its RD-
MTD, DHA-dFdC significantly prolonged the survival of L1210 leukemia-bearing mice.  
Conclusion: DHA-dFdC has dose-limiting toxicity, affecting mainly spleen at a lethal-RD. At or 
below its RD-MTD, DHA-dFdC is effective against leukemia in a mouse model.  
  
                                               
1 Published in: Valdes S, Naguib YW, Finch RA, Baze WB, Jolly CA, Cui Z. Preclinical Evaluation of the Short-
Term Toxicity of 4-(N)-Docosahexaenoyl 2 ́, 2 ́-Difluorodeoxycytidine (DHA-dFdC). Pharmaceutical Research. 





Gemcitabine (2`, 2`-difluorodeoxycytidine, dFdC) is a nucleoside analogue approved for 
the treatment of solid tumors such as pancreatic, non-small lung, breast, and ovarian cancers (1-
5). However, many factors limit its use in cancer treatment, such as its short half-life and tumor 
cell development of resistance (6, 7). Data from clinical studies showed a mild to moderate toxicity 
of gemcitabine (1, 8). The most common side effects are myelosuppression, high levels of 
hepatoxicity, renal toxicity, thrombocytopaenia, and anemia (1, 8, 9).  
Docosahexaenoic acid (DHA) is a natural omega-3 polyunsaturated fatty acid (PUFAs) 
with six cis double bonds (10). Since DHA cannot be synthesized by mammals, it is obtained from 
dietary sources such as fatty cold-water fish and fish oils (10). Data from many studies suggested 
that DHA has anticancer activity. For example, DHA has an inhibitory effect on breast cancer cells 
lines (11), induces apoptosis in breast and colon cancer cell lines (12), and inhibits angiogenesis 
through the inhibition of important angiogenic mediators (e.g. vascular endothelial growth factor, 
cyclo-oxygenase 2, nitric oxide, matrix metalloproteinases, etc.) (13). In addition, there are reports 
that DHA is able to inhibit tumor cell invasion and metastasis (14, 15), and data from a recent 
study suggested that the antitumor activity of DHA may be related to its ability to increase drug 
transportation across tumor cell membrane (16). Toxicity study in animals and human 
demonstrated that the consumption of DHA is safe. For example, data from a 90-day subchronic 
toxicity study showed that DHA is safe in rats at 0.5 and 1.25 g/kg body weight/day (17) . Clinical 
studies of DHA supplementation in adults did not show adverse effects in lipid levels (18, 19), 
platelet function (20, 21), or immune function (22, 23).  
In spite of the promising results of the antitumor activity of omega-3 PUFAs in cell culture 
and in animal models, data from clinical studies do not support an anti-neoplastic activity by 
omega-3 PUFAs. Most clinical trials supported the role of PUFAs in cancer prevention, as 
adjuvants in improving chemotherapy, and preventing cachexia (24-30). For example, VITAL 
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cohort study reported that the incidence of pancreatic cancer was inversely related to the uptake of 
DHA (24). Another study showed that the supplementation of omega-3 PUFAs such as 
eicosapentaenoic acid and DHA through parental nutrition improves hepatic and pancreatic 
function in patients with major abdominal surgery for pancreatic or gastrointestinal cancer (31). 
This improvement has been associated with the role of omega-3 PUFAs in inflammation. For 
example, the use of gemcitabine plus i.v. omega-3 fatty acid rich lipid emulsion (e.g. LipidemÒ) 
in pancreatic cancer patients improves their outcomes through reduction in circulating pro-
angiogenic platelet-derived growth factor and fibroblast growth factor and pro-inflammatory 
factors (e.g. interleukin-6 and -8) (26, 27).  
Previously, in an effort to exploit the antitumor activity of both gemcitabine and DHA, we 
synthesized a new compound, DHA-dFdC, by covalently conjugating DHA to dFdC at the 4-N 
position of dFdC (32). DHA-dFdC is a pale yellow waxy solid with a melting point of 96º C. It is 
poorly soluble in water (i.e. 25.2 ± 11.2 µg/ml) and has a logP value of 2.2 ± 0.3 (32). DHA-dFdC 
has potent cytotoxicity against a broad-spectrum of human and mouse tumor cell lines and showed 
significant antitumor activity in several mouse models of pancreatic cancer, including Kras-Ink4a 
genetically-modified mice and nude mice with orthotopically implanted human Panc-1 tumor cells 
(32). Importantly, in both tumor cells in culture and in animals, DHA-dFdC is significantly more 
effective than the molar equivalent DHA and dFdC physically mixed (32), suggesting a unique 
mechanism of antitumor activity by the DHA-dFdC conjugate. In the present study, we tested the 
short-term toxicity of DHA-dFdC in healthy DBA/2 mice by identifying its RD-MTD, a lethal-
RD, and the major organ(s) and blood and serum parameters affected by DHA-dFdC at the lethal-
RD. Finally, the antitumor activity of DHA-dFdC at or below its RD-MTD was also evaluated in 




2.3 MATERIALS AND METHODS 
 
2.3.1 Synthesis and formulation of DHA-dFdC  
DHA-dFdC was synthesized following our previously reported conjugation scheme (32). 
The purity of the resultant DHA-dFdC was confirmed by NMR and Mass Spectrum analyses. 
DHA-dFdC was dissolved in a vehicle solution that consists of Tween 80 (10%, w/v), ethanol (5.2 
%, v/v), and mannitol (5%, w/v) in water. 
 
2.3.2 Cell lines 
L1210 cells (mouse leukemia cell line) were from the American Type Culture Collection 
(Manassas, VA). Cells were grown in DMEM supplemented with 10% horse serum, 100 U/ml of 
penicillin, and 100 mg/ml of streptomycin. All cell culture medium and reagents were from 
Invitrogen (Carlsbad, CA). 
 
2.3.3 Short-term repeated dose toxicity studies 
The animal protocol was approved by the Institutional Animal Care and Use Committee at 
The University of Texas at Austin. Toxicity studies were performed using healthy DBA/2 mice 
(5-6 weeks) from Charles River Laboratories (Wilmington, MA). For all the toxicity studies, a 
mouse weight loss of ≥ 20% of its initial body weight on day 0 was considered as the end point 
(33, 34). 
Initially, a single dose acute toxicity study was completed. Mice (n = 6, half male, half 
female) were intravenously (i.v.) injected once with DHA-dFdC at 85 mg/kg or 100 mg/kg. 
Untreated mice were used as a negative control. Mice were regularly monitored for overall health, 
and body weight was measured on days 3 and 6. On days 6, mice in the 100 mg/kg dose group and 
the untreated group were euthanized; major organs (i.e. heart, kidneys, liver, spleen, pancreas, and 
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lung) were collected and weighed. Experimental data for organ weights were expressed as the 
relative organ weight calculated as: (organ weight (g)/body weight (g)) x 100%. The percent of 
body weight change was similar in both treated groups, and there is not any significant difference 
in the relative organ weights in mice that received 100 mg/kg of DHA-dFdC or were left untreated 
(data not shown). An i.v. bolus dose of more than 100 mg/kg of DHA-dFdC was not attempted 
due to the limited solubility of DHA-dFdC in the vehicle solution, prompting us to focus on testing 
the toxicity of the DHA-dFdC on a repeat-dose schedule only.  
A five-dose schedule (e.g. injection on days 0, 3, 7, 10, and 13) was adopted for short-term 
repeated dose toxicity studies. Mice (n = 8, half male, half female) were i.v. injected with DHA-
dFdC at different doses: 70 mg/kg, 60 mg/kg, 53 mg/kg, 50 mg/kg, 40 mg/kg, or 0 mg/kg (i.e. 
vehicle control). An additional group of mice was left untreated as a negative control. Mice were 
regularly monitored for overall health, body weight change, and survival until 2 weeks after the 
last injection. The body weight of mice was recorded on days 0, 3, 7, 10, 13, 17, 21, 24, 28, and 
31.  
To identify a lethal-RD of DHA-dFdC, mice (n = 8, half male, half female) were i.v. 
injected with 100 mg/kg of DHA-dFdC three times on days 0, 3, and 5. Again, this dose was 
selected due to the limited solubility of DHA-dFdC in the vehicle solution. Mice in the control 
groups were left untreated or i.v. injected with vehicle solution (i.e. 0 mg/kg of DHA-dFdC). Mice 
were monitored every day, weighed on days 0, 2, 4, and 6, and euthanized on day 6.  
 
2.3.4 Effect of DHA-dFdC at RD-MTD or a lethal-RD on major mouse organ weights and 
blood and serum parameters  
Two experiments were carried out. In the first experiment, DBA/2 mice (n = 8, half male, 
half female) were i.v. injected with DHA-dFdC at 50 mg/kg on days 0, 3, 7, 10, and 13. As a 
control, another group of mice were left untreated. Five days after the last injection, mice were 
euthanized. Major organs were harvested, weighed, and reported as the weights relative to the 
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body weight of individual mouse. Blood samples were collected and shipped to IDEXX 
Laboratories (Sacramento, CA) for blood and serum parameter analyses. 
In another experiment, mice (n = 8, half male, half female) were i.v. injected with DHA-
dFdC at 100 mg/kg on days 0, 3, and 5. As controls, mice were either left untreated or i.v. injected 
with the vehicle solution alone. On day 6 mice were euthanized. Major organs were harvested and 
weighed. Blood samples were collected and shipped to IDEXX Laboratories for blood and serum 
parameter analyses.  
 
2.3.5 Evaluation of the antitumor activity of DHA-dFdC in a mouse model of leukemia 
Female DBA/2 mice (5-6 weeks) were intraperitoneally (i.p.) injected with the syngeneic 
L1210 leukemia cells (1 x 105) on day 0 to establish a mouse leukemia model (35, 36). Mice were 
then randomized into groups (n = 7) of untreated, vehicle alone, 1 x RD-MTD (i.e. 50 mg/kg), ¾ 
x RD-MTD (i.e. 37.5 mg/kg), and ½ x RD-MTD (i.e. 25 mg/kg), i.v. injected on days 1, 4, 8, 11, 
and 14, and monitored daily for overall health, weight change and survival (37). A mouse weight 
gain ≥ 60% of its initial body weight on day 0 was considered the end point (33, 34). Experimental 
data were reported as the mean survival time and T/U, which is defined as the ratio of the mean 
survival time of the treated group (T) divided by the mean survival time of the untreated group 
(U).  
 
2.3.6 Statistical analysis 
All statistical analyses involving comparing two groups were completed using Student´s t-
test. For comparison of more than two groups, one-way ANOVA followed by a Bonferroni post 
hoc test was used to determine statistical significance between groups. Mouse survival data were 
analyzed using the Log-rank (Mantel-Cox) test to determine the level of significance. All of the 
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analyses were performed with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Data 




2.4 RESULTS  
 
2.4.1 Identification of the RD-MTD of DHA-dFdC in healthy mice 
A repeat-dose range finding study was performed to identify the RD-MTD of DHA-dFdC. 
Mice were i.v. injected with DHA-dFdC at various doses on days 0, 3, 7, 10, and 13. As shown in 
Fig. 1A, the highest dose tested (i.e. 70 mg/kg) caused significant body weight loss in mice, as 
compared with untreated groups (e.g. p < 0.05 vs. Untreated, from day 5 to day 10). In addition, 
in the 70 mg/kg, 60 mg/kg, and 53 mg/kg groups, some mice reached the end point (i.e. body 
weight loss of ³ 20%) (Fig. 2.1B). On the other hand, DHA-dFdC at 50 mg/kg did not cause any 
mortality or body weight loss of ≥ 20% (Fig. 2.1A and 2.1B), and the mean mouse body weight 
changes did not show any difference when compared with the untreated group (Fig. 2.1A). 
Moreover, at 40 mg/kg, DHA-dFdC did not cause mortality, body weight loss of ≥ 20%, or any 
sign of toxicity in a separate experiment (Fig. 2.1C). Therefore, 50 mg/kg is considered the RD-






























Fig. 2.1 Identification of the RD-MTD of DHA-dFdC following five i.v. injections (on days 
0, 3, 7, 10, and 13 (▲)) in healthy DBA/2 mice (n = 8). (A) Percent of body weight 
change (* p < 0.05, 70 mg/kg vs. Untreated, one-way ANOVA followed by a 
Bonferroni post hoc test). (B) Survival curves. Log-rank (Mantel-Cox) test did not 
reveal any significant difference among groups. (C) Percent of body weight change 
at 40 mg/kg of DHA-dFdC. Student’s t-test did not reveal any difference). In A and 
C, data shown are mean ± S.D.  





































































2.4.2 Effect of DHA-dFdC at its RD-MTD on organ weights and blood and serum 
parameters in healthy mice  
DHA-dFdC was given (i.v.) to healthy mice at its RD-MTD and the weights of major 
organs were measured at the end of the study. As shown in Fig. 2.2, at RD-MTD, DHA-dFdC did 
not significantly affect the weight of any of the major organs tested. In addition, at RD-MTD, 
DHA-dFdC did not cause any significant change in the blood or serum parameters tested, as 













Fig. 2.2 Effect of DHA-dFdC at its RD-MTD on major mouse organ weights. Shown are 
relative organ weights (vs. body weights) 6 days after the completion of a schedule 
of five i.v. doses of DHA-dFdC at its RD-MTD. Data shown are mean ± S.D. (n = 











































Table 2.1 Blood and serum parameters in healthy mice 5 days after the last dose of DHA-
dFdC at its RD-MTD. Data are mean ± S.D. (n = 6-8).  
Parameter Unit 
RD-MTD (50 mg/kg) 
Untreated DHA-dFdC 
Blood       
White blood cells (WBC) k/µl 8.0 ± 3.5 5.4 ± 2.3 
Red blood cell count (RBC) M/ µl 10.1 ± 1.1 9.4 ± 1.0 
Hematocrit (HCT) % 40.0 ± 3.5 39.2 ± 4.2 
Mean globular volume (MCV) fL 39.8 ± 1.9 41.8 ± 1.7 
Mean corpuscular hemoglobin (MCH) pg 14.0 ± 0.3 14.5 ± 1.0 
Mean corpuscular hemoglobin 
concentration (MCHC) 
g/dL 35.3 ± 2.1 34.8 ± 2.7 
Lymphocytes % 79.9 ± 9.6 84.4 ± 7.8 
Monocytes % 5.5 ± 2.6 7.0 ± 3.9 
Basophil % 0.6 ± 1.0 0.2 ± 0.4 
Eosinophil % 2.9 ± 2.4 1.7 ± 1.6 
Neutrophil Segmented  % 11.1 ± 7.6 6.8 ± 6.9 
Platelet estimate  Adequate Adequate 
Serum    
Cholesterol mg/dL 116.7 ± 17.0 127.6 ± 23.3 
Glucose mg/dL 262.5 ± 70.9 270.8 ± 39.7 
Calcium mg/dL 9.4 ± 2.2 7.0 ± 5.6 
Phosphorus mg/dL 14.6 ± 3.3 16.4 ± 1.5 
Blood urea nitrogen (BUN) mg/dL 23.5 ± 4.0 23.4 ± 1.7 
Student’s t-test did not reveal any significant different between Untreated and DHA-dFdC 
groups 
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Table 2.1 (continued)    
Globulin g/dL 2.8 ± 0.5 2.7 ± 0.2 
Total bilirubin mg/dL 0.3 ± 0.1 0.2 ± 0.04 
Total proteins g/dL 6.0 ± 0.6 6.0 ± 0.2 
Aspartate transaminase (AST) U/L 689.5 ± 599.5 1266.0 ± 808.9 
Alanine transaminase (ALT) U/L 116.7 ± 115.2 154.2 ± 115.2 
Alkaline phosphatase (ALP) U/L 158 ± 39.4 145.0 ± 66.3 
Albumin g/dL 3.2 ±0.3 3.3 ± 0.2 





2.4.3 Effect of a lethal-RD of DHA-dFdC on healthy mice 
In order to identify a dose of DHA-dFdC that is lethal to DBA/2 mice, healthy mice were 
i.v. injected with three doses of DHA-dFdC at 100 mg/kg (i.e. on days 0, 3, and 5). Following the 
second dose, physical signs of toxicity observed include marked piloerection, transient paralysis, 
and little peer interactions. One day after the third dose, 50% of mice reached the end point (i.e. 
mortality or body weight loss of ≥ 20%) (Figs. 2.3A and 2.3B). Therefore, 100 mg/kg in a spaced 

























Fig. 2.3 Effect of a lethal-RD of DHA-dFdC following three i.v. injections (on days 0, 3, and 
5 (▲)) on healthy DBA/2 mice (n = 8, half male, half female). (A) Survival curves 
(** p < 0.01, Lethal-RD vs. Untreated, Log-rank (Mantel-Cox) test). (B) Percent of 
body weight change. Data are mean ± S.D.  
 
 
To identify the effect of a lethal-RD of DHA-dFdC on the main organs of mice, DHA-
dFdC was i.v. injected to healthy mice at 100 mg/kg on days 0, 3, and 5, and the weight of major 
organs were measured at the end of the study (i.e. day 6). As shown in Fig. 2.4, the relative weights 
of the spleen and liver in mice that received the DHA-dFdC at the lethal-RD were significantly 















































lower than that of the untreated mice, whereas the vehicle in which the DHA-dFdC was dissolved 
in did not significantly affect the weights of any of the organs. At the lethal-RD, DHA-dFdC 
significantly affected some blood parameters, including the white blood cells (WBC), red blood 
cell count (RBC), hemoglobin level (HGB), hematocrit value (HCT), lymphocytes, eosinophil, 
and neutrophil segmented (i.e. neutrophil segs), as compared to mice in the untreated group (Table 
2.2). In addition, the levels of some serum parameters such as phosphorus, blood urea nitrogen 
(BUN), and creatine phosphokinase (CPK) decreased in the lethal-RD group, as compared with 
the untreated group (Table II). Albumin also decreased in the lethal-RD group as compared with 













Fig. 2.4 Effect of DHA-dFdC at a lethal-RD on major organ weights of healthy mice. Shown 
are relative organ weights one day after the completion of three i.v. doses of DHA-
dFdC at 100 mg/kg. Data shown are mean ± S.D. (n = 6-8) (* p < 0.05, Lethal-RD 









































Table 2.2 Blood and serum parameters in healthy mice one day after three i.v. doses of DHA-dFdC at a lethal-RD (100 mg/kg). Data 
are mean ± S.D. (n = 8). 
Parameter Unit Treatment 
  Untreated Vehicle DHA-dFdC 
Blood     
White blood cells (WBC) k/µl 5.2 ± 1.7 5.3 ± 2.1 3.2 ±1.4a, b 
Red blood cell count (RBC) M/ µl 9.7 ± 0.5 9.2 ± 0.7 7.9 ± 2.0a 
Hemoglobin 
(HGB) 
(g/dL) 13.8 ± 0.9 13.8 ± 1.1 11.7 ± 2.5a, b 
Hematocrit (HCT)  % 39.8 ± 3.2 38.2 ± 2.1 32.0 ± 7.5a, b 
Mean globular volume (MCV) fL 41.0 ± 3.8 41.4 ± 1.8 41.0 ± 2.0 
Mean hemoglobin quantity (MCH) pg 14.3 ± 1.1 14.9 ± 0.5 15.1 ± 1.2 
Mean cellular hemoglobin concentration (MCHC) g/dL 35.0 ± 4.1 36.2 ± 2.3 36.9 ± 2.5 
Lymphocytes % 69.9 ± 9.7 75.1 ± 14.4 84.7 ± 6.2a 
Monocytes % 9.2 ± 9.0 6.7 ± 2.0 8.5 ± 2.9 
Basophil % 1.0 ± 1.5 2.1 ± 2.6 1.4 ± 2.9 
Statistical analysis was performed using one-way ANOVA followed by a Bonferroni post hoc test. 
a p < 0.05 vs. Untreated; b p < 0.05 vs. Vehicle; ¥ 7 adequate, 1 decreased. 
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Table 2.2 (continued) 
Eosinophil % 3.8 ± 3.0 2.8 ± 1.6 0.8 ± 1.2 a, b 
Neutrophil Segmented % 16.1 ± 5.6 13.4 ± 12.3 4.6 ± 3.6 a 
Platelet estimate  Adequate Adequate Adequate 
Serum     
Cholesterol mg/dL 103.7 ± 22.3 99.7 ± 9.2 94.6 ± 17.5 
Glucose mg/dL 230.4 ± 44.0 199.7 ± 37.5 210.1 ± 45.4 
Calcium mg/dL 9.9 ± 1.7 8.8 ± 3.4 9.9 ± 0.8 
Phosphorus  mg/dL 14.3 ± 1.7 13.8 ± 1.5 11.9 ± 1.7a 
Bicarbonate  (mmol/L) 28.9 ± 2.7 33.3 ± 2.8 31.6 ± 4.8 
Blood urea nitrogen (BUN) mg/dL 22.1 ± 3.0 20.5 ± 2.2 17.9 ± 1.96 a, b 
Globulin g/dL 2.7 ± 0.1 2.7 ± 0.2 2.7 ± 0.1 
Total bilirubin mg/dL 0.3 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 
Direct bilirubin mg/dL 0.1 ± 0.04 0.1 ± 0.05 0.1 ± 0.05 
Indirect bilirubin mg/dL 0.2 ± 0.08 0.3 ± 0.1 0.2 ± 0.08 
 
Statistical analysis was performed using one-way ANOVA followed by a Bonferroni post hoc test.  
a p < 0.05 vs. Untreated; b p < 0.05 vs. Vehicle; ¥ 7 adequate, 1 decreased. 
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Table 2.2 (continued) 
Aspartate transaminase (AST) U/L 200.6 ± 91.6 279.9 ± 165.3 193.9 ± 69.3 
Alanine transaminase (ALT) U/L 21.3 ± 3.0 25.9 ± 8.0 18.8 ± 5.1 
Alkaline phosphatase (ALP) U/L 200.3 ± 29.1 161.9 ± 70.2 182.6 ± 21.6 
Creatine phosphokinase (CPK) U/L 1033.7 ± 609.6 1923.3 ± 1248.2 822.4 ± 451.6b 
Albumin g/dL 2.8 ± 0.1 2.5 ± 0.3a 2.4 ± 0.2a 
 
Statistical analysis was performed using one-way ANOVA followed by a Bonferroni post hoc test.  





2.4.4 Efficacy of DHA-dFdC at or below its RD-MTD in vivo 
The RD-MTD identified above was in DBA/2 mice, and therefore DBA/2 mice were i.p 
injected (on day 0) with the syngeneic L1210 leukemia cells to establish a mouse model of 
leukemia to evaluate the antitumor activity of DHA-dFdC at or below its RD-MTD. Mice were 
inoculated on day 0, and then received (i.v.) five doses of DHA-dFdC on days 1, 4, 8, 11, and 14. 
Mice in the control groups (untreated mice and vehicle alone) were sacrificed on day 18, because 
they reached our end point (i.e. body weight increase of ≥ 60%) (Figs. 2.5A and 2.5B). Those mice 
presented larger distended abdomens, urine staining, and thin body conditions. In contrast, mice 
treated with DHA-dFdC at or below its RD-MTD did not gain more than 10% of body weight (Fig. 
2.5B), and they appeared normal on day 18. Mice that were treated with DHA-dFdC at or below 
its RD-MTD survived longer than mice in the control groups (Fig. 2.5A and Table 2.3). DHA-
dFdC at its RD-MTD (50 mg/kg) showed a higher T/U ratio than at 3/4 x RD-MTD (37.5 mg/kg) 
or at 1/2 x RD-MTD (25 mg/kg) (Table 2.3). Furthermore, DHA-dFdC at its RD-MTD increased 

































































Fig. 2.5 Efficacy of DHA-dFdC against L1210 leukemia cells in a mouse model. Tumor cells 
were injected (i.p.) on day 0. On days 1, 4, 8, 11, and 14 (▲), mice (n = 7) were i.v. 
injected with DHA-dFdC at 1 x RD-MTD, ¾ x RD-MTD, or ½ x RD-MTD. Mice in 
control groups were i.v. injected with vehicle alone or left untreated. (A) Survival 
curves (*** p < 0.0001, all DHA-dFdC groups vs. Untreated, Log-rank (Mantel-Cox) 
test). (B) Percent of body weight change. Data shown are mean ± S.D. (*** p < 
0.0001, all DHA-dFdC groups vs. Untreated, one-way ANOVA followed by 




























































Table 2.3 Antitumor activity of DHA-dFdC at 1 x RD-MTD, ¾ x RD-MTD, and ½ x RD-MTD 







(day) T/U* % ILS+ 
Untreated - - 18 1.0 0 
Vehicle 0 1, 4, 8, 11, 14 18 1.0 0 
1 x RD-MTD 50 1, 4, 8, 11, 14 26.0 ± 2.3a, b 1.4 ± 0.13a, b 44.4 
3/4 x RD-MTD 37.5 1, 4, 8, 11, 14 22.9 ± 1.2a, b 1.3 ± 0.07a, b 27.0 
1/2 x RD-MTD 25 1, 4, 8, 11, 14 21.9 ± 1.2a, b 1.2 ± 0.07a, b 21.4 
 
* The ratio of the mean survival time of treated group to the median survival time of the 
untreated group.  
+ Increase in life span compared to untreated group.  
Statistical analysis was performed using one-way ANOVA followed by a Bonferroni post 
hoc test. 
a p < 0.0001 vs. Control groups (i.e. Untreated and Vehicle);  





The repeat-dose range finding study showed that DHA-dFdC has a dose-dependent toxicity 
in terms of body weight and survival (i.e. weight loss of > 20%). Its RD-MTD is 50 mg/kg (Figs. 
2.1 - 2.2 and Table 2.1). At or below its RD-MTD, DHA-dFdC is effective in prolonging mouse 
survival in a mouse leukemia model (Fig. 2.5). However, higher doses of DHA-dFdC following a 
repeat-dose schedule affected the survival and body weight of the mice significantly (Figs. 2.1A 
and 2.1B). 
A single i.v. dose of DHA-dFdC at 100 mg/kg was not lethal to mice (data not shown). 
Due to the limited solubility of DHA-dFdC in the vehicle solution, we tested whether multiple 
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doses of DHA-dFdC at 100 mg/kg in a spaced schedule is lethal to mice. Mice were i.v. injected 
with DHA-dFdC at 100 mg/kg three times on days 0, 3, and 5. At this dosing regimen, around 50% 
of mice reached the end point (i.e. ³ 20% of body weight loss) as shown Figs. 2.3A and 2.3B. In 
addition, the spleen and liver weights of those mice decreased significantly in comparison to mice 
in the control groups (Fig. 2.4A). Furthermore, at this lethal-RD, DHA-dFdC showed 
hematological toxicity, because certain blood parameters (e.g. WBC, RBC, HGB, HCT, 
lymphocytes, eosinophil, and neutrophil segmented) were significantly different from that of mice 
in the untreated group (Table 2.2). Gemcitabine has dose-limiting toxicities in clinics. For 
example, data from clinical studies showed that gemcitabine causes dose-limiting 
myelosuppression that is characterized mainly by thrombocytopenia (1, 8). In our study, at a lethal-
RD dose, DHA-dFdC significantly decreased the levels of WBC as well as RBC, when compared 
to the control groups (40% and 18%, respectively) (Table 2.2). On the other hand, our data showed 
that platelet estimate was adequate, indicating that DHA-dFdC may not cause significant 
thrombocytopenia. At the lethal-RD used, DHA-dFdC also induced a significant decrease in the 
levels of HGB and HCT (15% and 20%, respectively), indicating DHA-dFdC induces anemia in 
DBA/2 mice (38, 39). The neutrophil levels in mice that received the lethal-RD of DHA-dFdC 
decreased significantly as compared to the untreated group (71%), indicating an acute neutropenia. 
It was reported that the number of WBC decreased in healthy men when they received a diet 
supplemented with DHA (22). The main cause of reduction of WBC number was attributed to a 
reduction in the number of circulating neutrophils (22). In our study, we found that at lethal-RD, 
DHA-dFdC caused a decrease in the number of WBC as well as neutrophils segmented (Table 
2.2). Both the DHA and gemcitabine moieties in the DHA-dFdC may have contributed to the 
observed hematological toxicity. Some serum parameters such as phosphorus, BUN, CPK and 
albumin in mice that received DHA-dFdC at the lethal-RD were also decreased compared to the 
untreated group (Table 2.2), but these changes were not more than 20%. According a previous 
study (40), small changes in some parameters in toxicity studies are due to animals having a poor 
tolerance to the test article. Indeed, one of the most common effects of toxicity studies in rodents 
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is decreasing serum albumin concentration because small species have a rapid turnover of albumin 
(41). Finally, DHA-dFdC at the lethal-RD did not significantly affect serum levels of aspartate 
transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP), when 
compared to the untreated control, in spite of the finding that it caused a decrease in the relative 
weight of mouse liver (Fig. 2.4). Data from a previous phase II clinical study showed that the liver 
toxicity of gemcitabine was mild and transient (1).  
DHA is considered a generally recognized as safe material for inclusion in diet by the U.S. 
Food and Drug Administration (42). However, some side effects have been reported such as 
gastrointestinal disturbances, nausea, increased bleeding time, effects in the glycemic control in 
non-insulin-dependent diabetics, and increased levels of low-density lipoprotein cholesterol (42). 
Parenteral omega-3 fatty acid preparations have been used for years as part of total parenteral 
nutrition and are generally well tolerated (27, 43). In addition, an in vitro study reported that 
pancreatic stellate cells (PSCs) are highly sensitive to gemcitabine plus LipidemÒ (i.e. emulsion 
for infusion that contains omega-3-acid triglyceride) (44). As PSCs are responsible of therapeutic 
resistance of pancreatic cancer due to their contribution to secretion of extracellular matrix, the 
anti-proliferative and anti-invasive efficacy of gemcitabine plus LipidemÒ treatment reported in 




The RD-MTD of DHA-dFdC in a spaced schedule is 50 mg/kg when intravenously injected 
to DBA/2 mice. DHA-dFdC mainly affects mouse spleen at a lethal repeat dose. At or below its 
RD-MTD, DHA-dFdC shows anticancer activity in a mouse model of leukemia, improving the 
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Chapter 3: A Solid Lipid Nanoparticle Formulation of 4-(N)-Docosahexaenoyl 





Previously, we reported 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-
dFdC), a novel lipophilic compound with a potent, broad spectrum antitumor activity. Herein, we 
report a solid lipid nanoparticle (SLN) formulation of DHA-dFdC with improved apparent aqueous 
solubility and chemical stability. The SLNs were prepared from lecithin/glycerol monosterate-in-
water emulsions emulsified with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) and 
Tween 20. The resultant DHA-dFdC-SLNs were 102.2 ± 7.3 nm in diameter and increased the 
solubility of DHA-dFdC in water to at least 5.2 mg/mL, more than 200-fold higher than its intrinsic 
water solubility. As a comparison, the waxy solid of DHA-dFdC, even in the presence of vitamin 
E as an antioxidant, was unstable when stored at room temperature. However, after one-month of 
storage at the same condition, DHA-dFdC in lyophilized DHA-dFdC-SLNs powder did not 
significantly degrade. DHA-dFdC-SLNs also showed an increased cytotoxicity against certain 
tumor cells than DHA-dFdC. The plasma concentration of DHA-dFdC in mice intravenously 
injected with DHA-dFdC-SLNs in dispersion followed a bi-exponential model, with a half-life of 
~44 h. In mice with pre-established B16-F10 murine melanoma, DHA-dFdC-SLNs were 
significantly more effective than DHA-dFdC in controlling the tumor growth. In addition, 
histology evaluation revealed a high level of apoptosis and tumor encapsulation in tumors in mice 
treated with DHA-dFdC-SLNs. DHA-dFdC-SLNs represents a new DHA-dFdC formulation with 




Gemcitabine (2´, 2- difluorodeoxycytidine, dFdC) is a nucleoside analogue approved for 
treatment of pancreatic, lung, breast, and ovarian cancer by slow intravenous infusion (1-4). In an 
effort to improve the efficacy of gemcitabine, we previously synthesized a new compound DHA-
dFdC by conjugating docosahexaenoic acid (DHA), a omega-3 polyunsaturated fatty acid (PUFA), 
to dFdC on the 4-N position (5). DHA-dFdC showed potent and broad spectrum antitumor activity 
against NCI-60 DTP human tumor cell lines and was significantly more effective than the molar 
equivalent dose of gemcitabine in controlling pancreatic tumor growth in several mouse models 
of pancreatic cancer, including a genetically engineered mouse model and athymic mice with 
orthotopically implanted human pancreatic tumor cells (5). The repeat dose-maximum tolerated 
dose of DHA-dFdC in a Tween 80-ethanol in water solution was found to be 50 mg/kg in C57BL/6 
mice (6). However, DHA-dFdC is poorly soluble in water (i.e. intrinsic solubility, ~25 µg/mL) and 
is not chemically stable in the current Tween 80-ethanol in water formulation (5).  
SLNs have emerged as an attractive delivery system for poorly water-soluble drugs (7-9). 
There is also evidence that incorporation of drug into SLNs can increase its chemical stability (10-
12). Previously, our group developed a SLN formulation based on a lecithin/glycerol monostearate 
(GMS)-in-water emulsion (13-15). In the present study, to improve the (apparent) water solubility 
and the chemical stability of DHA-dFdC, we developed a new DHA-dFdC SLN formulation 
(DHA-dFdC-SLNs) by incorporating DHA-dFdC into SLNs prepared by emulsifying 
lecithin/GMS-in-water emulsions with Tween 20 and TPGS (or vitamin E TPGS) (13, 14). TPGS 
is a water-soluble derivate of natural vitamin E, which is formed by esterification of vitamin E 
succinate with polyethylene glycol (PEG) (16). TPGS is widely used in pharmaceutical 
formulations as an emulsifier, solubilizer, absorption enhancer, permeation enhancer, and/or 
stabilizer (16-19). There is also evidence that TPGS has a stronger antioxidant activity than a-
tocopherol or vitamin E (20, 21). Moreover, TPGS is a P-gp inhibitor and can help overcome 
multidrug resistance by tumor cells (16, 19, 22, 23). Furthermore, data from several studies showed 
that TPGS induces apoptosis and has a synergic effect with certain cancer chemotherapeutic agents 
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such as docetaxel, paclitaxel, and doxorubicin (23-27). Finally, we also evaluated the plasma 
pharmacokinetics of DHA-dFdC in the DHA-dFdC-SLNs in a mouse model, the cytotoxicity of 
the DHA-dFdC-SLNs against several tumor cell lines in vitro, and the antitumor activity of the 
DHA-dFdC-SLNs in a mouse model with B16-F10 murine melanoma cell. 
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3.3 MATERIALS AND METHODS 
 
3.3.1 Materials and cell lines 
Mannitol, Tween 20, GMS, TPGS, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), Tween 80, mannitol, and sucrose were from Sigma-Aldrich (St. Louis, MO). 
Gemcitabine HCl was from Biotang, Inc. (Lexington, MA). Soy lecithin was from Alfa Aesar 
(Ward Hill, MA). Ethyl acetate (EtOAc), dimethyl sulfoxide, tetrahydrofuran (HPLC-grade), 
isopropanol, and methanol (HPLC-grade) were from Thermo Fisher (Waltham, MA). Float-A-
LyzerÒG2 dialysis device (MWC 50 kD) was from Spectrum Inc. (New Brunswick, NJ) 
B16-F10 murine melanoma cell and TC-1 murine lung cancer cell lines were from the 
American Type Culture Collection (Manassas, VA). M-Wnt cells (murine mammary gland cell 
lines) were from Dr. Stephen D. Hursting’s lab at The University of North Carolina, Chapel Hill. 
B16-F10 and TC-1 cells were grown in DMEM and RPMI 1640, respectively (Invitrogen, 
Carlsbad, CA). M-Wnt cells were grown in a similar medium as TC-1, with an additional 
supplement of 1% Glutamax (GlutaMAXÔSupplement, GibcoÒ). All media were supplemented 
with 10% (v/v) fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 μg/mL of streptomycin, 
all from Invitrogen (Carlsbad, CA).  
 
3.3.2 Preparation and characterization of 4-(N)-docosahexaenoyl 2′,2′-
difluorodeoxycytidine solid lipid nanoparticles (DHA-dFdC-SLNs) 
3.3.2.1 Preparation of DHA-dFdC-SLNs 
DHA-dFdC was synthesized following our previously reported conjugation scheme (5). 
The purity of the resultant DHA-dFdC was confirmed by NMR and Mass Spectrum. SLNs were 
prepared as previously described with some modifications (14). Briefly, 3.5 mg of soy lecithin, 0.5 
mg of GMS, and 0.875 mg of TPGS were weighed into a 7 mL glass vial. Eight hundred microliter 
of de-ionized and filtered (0.22 µm) water (80°C) was added into the lecithin/GMS/TPGS mixture, 
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which was then vortexed and sonicated for 3 min until a homogenous slurry was formed. The 
mixture was maintained on an 80°C hot plate surface for 5 min. A solution of Tween 20 (55 mg in 
1 ml of water) was prepared, and 200 µL of this solution was added drop wise into the mixture to 
reach a final concentration of 1% (v/v). The resultant emulsions were allowed to cool to room 
temperature while stirring to form SLNs. To incorporate DHA-dFdC into the SLNs, DHA-dFdC 
at various amounts (i.e. 5.2, 8.3, 9.8, or 14.3 mg) were added into the lecithin/GMS/TPGS mixture 
before the addition of water. The next steps were identical to the preparation of DHA-dFdC-free 
SLNs. The size and zeta potential of the SLNs were measured using a Malvern Zetasizer Nano ZS 
(Westborough, MA) 
 
3.3.2.2 Short-term stability study  
The stability of DHA-dFdC-SLNs prepared with 0, 5.2, 8.3, 9.8, or 14.3 mg of DHA-dFdC 
was evaluated at 4°C for 6 days. The size and zeta potential of the SLNs were measured using a 
Malvern Zetasizer Nano ZS (Westborough, MA). 
 
3.3.2.3 Transmission electron microscopy (TEM) 
The size and morphology of the DHA-dFdC-SLNs were examined using a transmission 
electron microscope available in the Institute for Cellular and Molecular Biology Microscope and 
Imaging Facility at The University of Texas at Austin. The carbon film-coated copper grid was 
glow discharged for 2 min. A sample of 10 µL of DHA-dFdC-SLNs suspended in water was 
deposited on the grid and left to stand for 1 min. The excess sample was removed with a filter 
paper. One drop of 1% uranyl acetate was added on the grid for 30 s. The sample was then observed 
under the TEM after removing the excess uranyl acetate fluid with filter paper (28).  
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3.3.2.4 Encapsulation efficiency (EE)  
The encapsulation efficiency of DHA-dFdC in SLNs was determined by an ultrafiltration 
method. Briefly, 1 mL of DHA-dFdC-SLNs was added into an ultrafiltration centrifuge tube (30 
kD, Amicon Ultra-4, Millipore) and centrifuged at 2844 rcf for 10 min. Then, 100 µl of the filtrate 
solution was taken from the bottom part of the ultrafiltration centrifuge tube to measure DHA-
dFdC concentration by high performance liquid chromatography (HPLC). To corroborate the 
detection method, the remaining suspension (»50 µl) in the ultrafiltration centrifuge tube was re-
dissolved with 950 µl water to extract the DHA-dFdC, according the procedure previously 
describe. 
 
3.3.2.5 Gel permeation chromatography (GPC) 
To separate potential micelles from DHA-dFdC-SLNs, GPC was performed using a 6 mm 
x 30 cm Sepharoseâ 4B column (13). Samples (100 µL) were applied into the column and eluted 
with de-ionized and filtered (0.22 µm) water. Elution fractions of 500 µL were collected. Particle 
concentration (i.e. kilo counts per second or Kcps) in each fraction was measured using a Malvern 
Zetasizer Nano ZS, and the concentration of DHA-dFdC in each fraction was determined using 
HPLC after extraction.  
 
3.3.3 Lyophilization of the DHF-dFdC-SLNs and their stability in lyophilized powder 
A 30% (w/v) stock solution of sucrose as lyoprotectant was prepared with de-ionized and 
filtered (0.2 µm) water. Then, 900 µL of DHA-dFdC-SLNs in water suspension was mixed with 
100 µL of the sucrose solution to obtain a final suspension with 3% (w/v) of sucrose. The DHA-
dFdC-SLNs in suspension were then stored at -20°C for 30 min, transferred to -80°C for 60 min, 
and finally transferred to a VirTis Advantage bench top tray lyophilizer (The VirTis Company, 
Inc. Gardiner, NY). Lyophilization was performed over 72 h at pressure less than 200 mTorr under 
nitrogen atmosphere. The shelf temperature was gradually ramped from -40°C to 26°C. After 
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lyophilization, the sample was quickly sealed and stored in a desiccator at room temperature, 
protected from light. To evaluate the physical and chemical stability of the DHA-dFdC-SLNs in 
the lyophilized powder, DHA-dFdC was extracted from the powder 0, 7, and 30 days later. Briefly, 
the lyophilized sample was reconstituted in 1 mL of de-ionized and filtered (0.2 µm) water. The 
reconstituted DHA-dFdC-SLN suspension (100 µL) was mixed with 100 µL of isopropanol, 
vortexed for 30 s, and maintained at room temperature for 5 min. Then, 600 µl of ethyl acetate was 
added, and the sample was vortexed for 30 s and centrifuged at 11,000 rcf for 20 min. The 
supernatant was collected into a glass vial and evaporated under nitrogen. The sample was re-
dissolved in 100 µL of THF, and the concentration was measured by HPLC.  
As a control, DHA-dFdC was dissolved in ethanol and mixed with vitamin E at final 
concentration of 5.047% (w/w) (5). The solution was dried under nitrogen, sealed, and stored at 
room temperature, protected from light, and the content of DHA-dFdC was measured at various 
time points 
 
3.3.4 In vitro stability of DHA-dFdC-SLNs in simulated biological media 
To evaluate the stability of the DHA-dFdC-SLNs in simulated biological media, the SLNs 
in suspension were diluted in phosphate-buffered saline (PBS, 10 mM, pH 7.4) with 10% FBS 
(v/v) and incubated at 37°C in a MaxQ 4000 Floor Shaker Incubator (Thermo Fisher Scientific, 
100 rpm) for 18 h. The particle size was measured at different time points using a Malvern 
Zetasizer.  
 
3.3.5 In vitro release of DHA-dFdC from DHA-dFdC-SLNs 
The release profile of DHA-dFdC from SLNs were evaluated by suspending DHA-dFdC-
SLNs at concentration of 127 µg/mL in release medium (1% (w/v) of Tween 20 dissolve in PBS), 
which were then placed into a 1 mL cellulose ester dialysis tube (MWC 50 kD) from Spectrum 
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Chemicals & Laboratory Products (New Brunswick, NJ). The dialysis tube was then placed into a 
plastic conical tube containing 13 mL of release medium to created sink conditions, which was 
incubated in a MaxQ 5000 Floor Shaker Incubator at 37°C and 100 rpm for 8 h. At predetermined 
time points, 200 µL of the release medium was withdrawn and replaced with 200 µL of fresh 
release medium. As a control, the diffusion of DHA-dFdC dissolved in a Tween 20 solution (i.e. 
127 µL g/mL of DHA-dFdC in 1% of Tween 20 in water) across the dialysis membrane was also 
measured. The concentration of the DHA-dFdC was determined by HPLC.  
 
3.3.6 HPLC 
HPLC analysis of DHA-dFdC was performed using an Agilent Infinity 1260 (Santa Clara, 
CA) with a RP-C18 column (Zorbax Eclipse, 5 μm, 4.5 mm × 150 mm, Santa Clara, CA). The 
mobile phase was methanol and water (90:10, v/v). The flow rate was 1.0 ml/min, and the detection 
wavelength and injection volume were 248 nm and 5 μL, respectively (5). 
 
3.3.7 In vitro cytotoxicity assay 
The cytotoxicity of DHA-dFdC-SLNs was evaluated in TC-1, B16-F10, and M-Wnt cells. 
Cells were seeded into 96-well plates (4000 cells/well for TC-1 and B16-F10 cells, 1000 cells/well 
for M-Wnt cells) and incubated at 37°C, 5% CO2 overnight. Cells were then treated with various 
concentrations of DHA-dFdC, DHA-dFdC-SLNs, DHA-dFdC-free SLNs, or dimethyl sulfoxide 
for up to 48 h. As a control, cells were treated with fresh medium. Cell survival was determined 
using an MTT assay (29). DHA-dFdC was dissolved in dimethyl sulfoxide and then diluted with 
cell culture media, whereas DHA-dFdC-SLNs and DHA-dFdC-free SLNs were dispersed directly 
in cell culture media. 
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3.3.8 Plasma pharmacokinetics (PK) of DHA-dFdC in DHA-dFdC-SLNs 
The animal protocol was approved by the Institutional Animal Care and Use Committee at 
The University of Texas at Austin. To evaluate the PK parameters, healthy female C57BL/6 mice 
(6-8 weeks, Charles River Laboratories, Wilmington, MA) were injected intravenously with DHA-
dFdC-SLNs dispersed in sterile mannitol 5% (w/v) at dose of 2 mg of DHA-dFdC per mouse. Mice 
were euthanized at various time points later (i.e. 0.25, 0.5, 1, 2, 4, 8, 24, and 48 h). Blood was 
collected into heparin-coated tubes, which were then centrifuged at 13000 rcf for 20 min to isolate 
plasma. Then 200 µL of the plasma was mixed with 200 µL of isopropanol and 200 µL cold PBS. 
The mixture was vortexed and incubated at 4°C for 5 min. Following the incubation, 1000 µL of 
ethyl acetate was added, and the mixture was vortexed for 5 min, and followed by centrifugation 
at 18,000 rcf for 5 min. The supernatant was collected and dried under nitrogen gas. Finally, the 
residue was re-dissolved in 100 µL of THF, which was then analyzed using HPLC (5). As an 
internal control, 4-(N)-stearoyl dFdC synthesized by conjugating stearate and dFdC on its 4-(N) 
position was added in the samples before extraction (13). Data were analyzed using PK SolverÒ, 
assuming a two-compartmental model (30). 
 
3.3.9 Evaluation of the antitumor activity of DHA-dFdC-SLNs in a mouse model 
Female C57BL/6 mice (18-20 g, 6-8 weeks) were subcutaneously (s.c.) injected with B16-
F10 (5 x 105 cells/mouse) in the right flank on day 0. Seven days later, mice were randomized in 
5 groups (n = 5-6) and i.v. injected with DHA-dFdC (1 mg/mouse, equivalent to 50 mg/kg) 
dissolved a vehicle solution (i.e. Tween 80 (10%, w/v), ethanol (5.2%, v/v), and mannitol (5%, 
w/v) in water), the vehicle solution (as a control) (5, 6), DHA-dFdC-SLNs (equivalent to 1 mg of 
DHA-dFdC/mouse), or the equivalent dose of DHA-dFdC-free SLNs; both SLNs were dispersed 
in sterile mannitol 5%, (w/v). As a control, one group of mice were left untreated. Treatments were 
repeated every 3 days for a total of 4 times. Mouse health and tumor growth were monitored daily. 
Tumor size was measured 2-3 times a week, and tumor volume was calculated as: volume (mm3) 
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= (length x width2)/2. Mice were euthanized 17 days after B16-F10 cell injection, and tumor tissues 
were collected for histology study. For mice that were left untreated, the length of some of the 
tumors reached 15 mm before day 17 and had to be euthanized earlier.  
 
3.3.10 Histology 
Tumor tissues were fixed in formalin, embedded, and stained with hematoxylin and eosin 
(H&E) in the Histological and Tissue Analysis Facility in the Dell Pediatric Research Institute at 
The University of Texas at Austin.  
 
3.3.11 Data analysis 
Statistical analyses were completed by one-way ANOVA followed by a Bonferroni post 
hoc test. A p value of £ 0.05 (two-tail) was considered significant. Most of the analyses were 
performed with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). PK parameters were 
obtained using PK Solver (30). 
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3.4 RESULTS AND DISCUSSION 
 
3.3.1 Preparation and characterization of DHA-dFdC-SLNs  
DHA-dFdC is a lipophilic compound with potent antitumor activity against various cancer 
cell lines in culture (e.g. pancreatic cancer, leukemia, kidney cancer) and in mouse models of 
pancreatic cancer and leukemia (5, 6). However, this compound presents solubility and stability 
issues (5). To increase its water solubility and improve its chemical stability, we developed a solid 
lipid nanoparticle formulation (13, 14). 
The particle diameter, polydispersity index, and zeta potential DHA-dFdC-SLNs loaded 
with various concentrations/amounts of DHA-dFdC are shown in Table 3.1. Statistical analysis 
did not reveal any significant differences on the particle sizes and zeta potentials of SLNs prepared 
with various amounts of DHA-dFdC. However, in a short stability study at 4°C, the DHA-dFdC-
SLNs prepared with 5.2 mg of DHA-dFdC remained stable after 6 days (Fig.3.1A-C) and were 
thus selected for further studies. This SLN formulation increases the apparent aqueous solubility 
of DHA-dFdC to 5.2 mg/ml, which may be further increased by concentrating the nanoparticles. 
Shown in Fig. 1D is the dynamic light scattering spectrum of DHA-dFdC-SLNs prepared with 5.2 
mg of DHA-dFdC. The TEM images of the DHA-dFdC-SLNs showed that they are spherical (Fig. 
3.1E) with particle size smaller than that determined by dynamic light scattering (Fig. 3.1D). The 
encapsulation efficiency of DHA-dFdC in the DHA-dFdC-SLNs was close to 100% since DHA-
dFdC was not detected in the filtrate after ultrafiltration. To corroborate this result, the suspension 
remained in the ultrafiltration centrifuge tube was re-dissolved in water to extract the DHA-dFdC, 
and 97% ± 21.4 (n = 6) of DHA-dFC was recovered. There are reports that TPGS as an emulsifier 
in paclitaxel-loaded polymeric nanoparticles helped to improve the encapsulation efficiency to 
100% (16, 17, 31). Due to the presence of Tween 20 and TPGS in our DHA-dFdC-SLN 
formulation, it is possible that a certain fraction of the DHA-dFdC may be in micelles. For instance, 
TPGS has a relative low critical micelle concentration of 0.02 % (w/w) at 37ºC, ~ 1% (w/v) for 
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Tween 20 at 20ºC (32, 33). GPC was applied to identify the extent to which DHA-dFdC is 
potentially incorporated into micelles (13). As shown in Fig. 3.1F, only one apparent DHA-dFdC 
peak can be identified in the GPC spectrum, which also overlaps with particle count spectrum, 





Table 3.1 Characterization of DHA-dFdC-SLNs prepared with different amounts of DHA-
dFdC. Data shown are mean ± S.D. (n = 3). 
DHA-dFdC (mg) 0 5.2 8.3 9.8 
Particle diameter (nm) 97.3 ± 13.6 102.2 ± 7.3 92.0 ± 3.6 96.5 ± 14.2 
Polydispersity index 0.27 ± 0.10 0.23 ± 0.01 0.24 ± 0.02 0.26 ± 0.02 








































Figure 3.1 continued next page 
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Fig. 3.1 (A-C) Effect of the amount of DHA-dFdC on the stability of the resultant DHA-
dFdC-SLNs. Shown are particle size (A), polydispersity index (B), and zeta potential 
(C) of the resultant DHA-dFdC-SLNs after 6 days of storage at 4°C. Data shown are 
mean ± SD (n = 3). (D) A representative particle size distribution curve of DHA-
dFdC-SLNs prepared with 5.2 mg of DHA-dFdC. (E) A representative TEM image 
of DHA-dFdC-SLNs prepared with 5.2 mg of DHA-dFdC (bar = 200 nm). (F) A 
presentative gel permeation chromatograph of DHA-dFdC-SLNs prepared with 5.2 
mg of DHA-dFdC. DHA-dFdC-SLNs were applied to a Sepharose 4B column, and 
the elution fraction was 0.5 mL. D and F, experiments were repeated at least three 


































3.4.2 Chemical stability of DHA-dFdC in DHA-dFdC-SLNs after lyophilization 
To select a proper lyoprotectant, we screened various sugars including sucrose, mannitol, 
and trehalose with concentrations ranging from 2.5% (w/v) to 5% (w/v) and found that sucrose at 
concentrations between 2.5% to 3% can effectively prevent particle size change after the DHA-
dFdC-SLNs were subjected to lyophilization and reconstitution (data not shown). Sucrose at 3% 
(w/v) was thus used as the lyoprotectant for further studies. As shown in Fig. 3.2A, the particle 
size of the DHA-dFdC-SLNs did not significantly change after 30 days of storage as a lyophilized 
powder at room temperature. Importantly, the content of DHA-dFdC in the lyophilized DHA-
dFdC-SLNs powder remained unchanged during the 30 days of storage (Fig. 3.2B). As a 
comparison, just 19.1% ± 7.0 of DHA-dFdC in the DHA-dFdC-vitamin E solid mixture was left 
after 14 days of storage in the same condition (p < 0.0001) (Fig. 3.2C). Previously, we reported 
that DHA-dFdC in a Tween 80-ethanol-water solution was unstable when storage at room 
temperature, with a half-life of ~14 h, while the addition of vitamin E (0.01%, w/v) in the solution 
helps to increase the stability of DHA-dFdC in the solution (5). The improved chemical stability 
of DHA-dFdC in the DHA-dFdC-SLNs dry powder may be attributed to the following three 
reasons. First, the SLNs may have protected DHA-dFdC incorporated in them from chemical 
degradation (9). For example, it was reported that b-carotene loaded in SLNs have improved 
stability because the b-carotene was protected against oxidation (9, 34). Second, the incorporation 
of TPGS in the formulation likely provided antioxidant properties since TPGS contains a-
tocopherol or vitamin E, and TPGS was reported to have more antioxidant activity than free a-


























Fig. 3.2 Stability of DHA-dFdC and DHA-dFdC-SLNs as a lyophilized powder. (A) Particle 
size of DHA-dFdC-SLNs. (B) The concentration of DHA-dFdC remaining in the 
DHA-dFdC-SLNs. The measures in A and B were performed on 0, 7 and 30 days 
after the DHA-dFdC-SLNs were lyophilized and stored at room temperature. (C) 
Chemical stability of DHA-dFdC in a dry waxy solid that contains 5.047% (w/w) of 
vitamin E when stored at room temperature for 14 days. *** p < 0.001. Data are mean 
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DHA-dFdC	(mg)	 0	 5.2	 8.3	 9.8	 14.32	
Particle	size	(nm)	 97.3	±	13.6	 102.2	±	7.3	 91.98	±	3.6	 96.5	±	14.2	 94.4	
Polydispersity	index	 0.286	±	0.1	 0.230	±	0.01	 0.241	±	0.02	 0.263	±	0.02	 0.27	




Parameter	 Unit	 Observed	 Parameter	 Unit	 Observed	
k10	 1/min	 0.0007	 Tmax	 min	 103.74	
k1/2	 1/min	 0.007	 Cmax	 µg/ml	 17.01	
k21	 1/min	 0.015	 t1/2α	 min	 66.05	
t1/2α	 min	 31.70	 t1/2β	 min	 1974.13	
t1/2β	 min	 1534.83	 t1/2Ka	 min	 62.81	
C0	 µg/ml	 17.23	 AUC0-24h	 (µg/ml)*min	 8607.96	
V	 (µg)/(µg/ml)		 116.09	 AUC0-inf	 (µg/ml)*min	 17011.89	
CL	 ((µg)/(µg/ml))/min	 0.076	 AUMC	 (µg/ml)*min2	 40298363.73	
V2	 (µg)/(µg/ml)	 51.66	 MRT	 min	 2368.84	
CL2	 ((µg)/(µg/ml))/min	 0.77	 V/F	 (µg)/(µg/ml)	 47.97	
AUC0-24h	 (µg/ml)*min	 12635.03	 CL/F	 ((µg)/(µg/ml))/min	 0.12	
AUC0-inf	 (µg/m )*min	 26150.18	 V2/F	 (µg)/(µg/ml)	 219.87	
AUMC	 (µg/ml)*min2	 57355290.12	 CL2/F	 ((µg)/(µg/ml))/min	 0.33	
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3.4.3 In vitro characterization of DHA-dFdC-SLNs 
The particles size of DHA-dFdC-SLNs after 18 h of incubation in a simulated biological 
medium (i.e. 10% FBS in PBS) at 37º C did not increase, suggesting that after intravenous 
administration, DHA-dFdC-SLNs will not likely aggregate. Shown in Fig. 3.3 is the release profile 
of DHA-dFdC from the DHA-dFdC-SLNs. Only 8.6% ± 1.9 of DHA-dFdC was released from the 













Fig. 3.3 In vitro release profile of DHA-dFdC from DHA-dFdC-SLNs. The diffusion of 
DHA-dFdC (in Tween 20 micelles) across the dialysis membrane was measured as 








3.4.4 Evaluation of the cytotoxicity of the DHA-dFdC-SLNs against tumor cells in culture 
The cytotoxicity of the DHA-dFdC-SLNs was evaluated by determining the survival of 
tumor cells after incubation with the SLNs using the MTT assay. As shown in Fig. 3.4A-B, DHA-
dFdC-SLNs were more cytotoxic than DHA-dFdC in M-Wnt (i.e. IC50 values of 0.92 µM versus 
2.15 µM, p < 0.05, 24 h of incubation) and B16F10 cells (i.e. IC50 values of 0.085 µM versus 1.81 
µM, p < 0.0001, 48 h of incubation). In TC-1 cells, the cytotoxicity of DHA-dFdC-SLNs was not 
significantly different from that of DHA-dFdC (Fig. 3.4C). DHA-dFdC-free SLNs and dimethyl 
sulfoxide (i.e. vehicle used to dissolve DHA-dFdC) did not show significant cytotoxicity in the 




































































Fig. 3.4 Cytotoxicity of DHA-dFdC-SLNs in M-Wnt cells (A), B16-F10 cells (B), and TC-1 
cells (C). In A, the cells were incubated with the nanoparticles for 24 h, 48 h for B 
and C. As controls, cells were also incubated with DHA-dFdC-free SLNs, DHA-
dFdC dissolved in DMSO or the equivalent concentration of DMSO, or cell culture 























































Data from previous studies support that TPGS improve the activity of nanoparticles by 
enhancing cell uptake and/or increasing cytotoxicity (16, 19, 22). For example, high cellular uptake 
and cytotoxicity of docetaxel were reported when docetaxel-loaded liposomes were coated with 
TPGS, as compared to PEGylated liposomes without TPGS (19). Other TPGS-emulsified 
nanoparticles or TPGS-based nanoparticles were also showed to have high cellular uptake and 
cytotoxicity in cell lines such as Caco-2, HT-29, MCF-7, C6 gliomas cells (16). In addition, some 
studies showed a synergic effect between TPGS and docetaxel, doxorubicin, and paclitaxel (23, 
24, 26). For DHA-dFdC, we have reported that it has potent cytotoxicity against many tumor cells, 
including the TC-1 cell, which may explain that incorporating it into SLNs may not necessarily 
further improve its cytotoxicity against all cell lines in culture (5).  
 
3.4.5 Plasma pharmacokinetic of DHA-dFdC in DHA-dFdC-SLNs 
Data in Fig. 3.5 showed the plasma DHA-dFdC levels in mouse plasma samples at different 
time points after intravenous injection of DHA-dFdC-SLNs. The elimination of DHA-dFdC in 
mouse plasma follows a bi-exponential model. Table 3.2 includes selected PK parameters of DHA-
dFdC. The AUC0-¥ values for DHA-dFdC was 677.3 µg/ml*h, and the plasma half-life of DHA-
dFdC in the elimination phase was ~44 h. For a comparison, previously, we reported that when 
DHA-dFdC was given in a Tween 80-ethanol-water solution to mice, its plasma half-life was only 















Fig. 3.5 Plasma DHA-dFdC concentration (µg/mL) at 
different time points (h) after DHA-dFdC-SLNs in 
suspension were intravenously injected into in 
C57BL/6 mice. The dose of DHA-dFdC was 2 mg 
per mouse. Data were fitted using PKSolver, 





Table 3.2 Plasma PK parameters of DHA-dFdC-SLNs when 
given intravenously to mice 
Parameter Unit Observed 
k10 1/h 0.02 
k1/2 1/h 0.32 
k21 1/h 0.58 
t1/2a h 0.76 
t1/2b h 43.95 
C0 µg/ml 16.85 
V ml  0.12 
CL ml/h 0.03 
V2 ml 0.07 
CL2 ml/h 0.04 
AUC0-24h (µg/ml)*h 362.82 
AUC0-inf (µg/ml)*h 677.30 
AUMC (µg/ml)*h2 42519.06 






















3.4.6 Evaluation of the antitumor activity of DHA-dFdC-SLNs in mouse model 
The antitumor activity of DHA-dFdC-SLNs was evaluated in mice with pre-established 
B16-F10 tumors. As shown in Fig. 3.6A, tumors grew aggressively when mice were left untreated 
or treated with the Tween 80-ethanol-in-water vehicle only. DHA-dFdC in solution and Blank-
SLNs (free-DHA-dFdC-SLNs) at the dosing regimen tested delayed the tumor growth by 4 days, 
but there were not any significant difference between the sizes of the tumors in mice treated with 
DHA-dFdC in solution or Blank-SLNs and the sizes of tumors in mice left untreated in all the days 
compared (Fig. 3.6A). DHA-dFdC-SLNs were most effective in inhibiting the tumor growth; the 
nanoparticle formulation delayed the tumor growth by close to 8 days, and the sizes of the tumors 
in mice that were treated with the DHA-dFdC-SLNs were significantly smaller than those in mice 
that were left untreated or treated with the DHA-dFdC in solution (Fig. 3.6A). There was not any 
significant difference in the body weights of mice among the groups during the treatments (Fig. 
3.6B), indicating DHA-dFdC-SLNs at the dosing regimen tested were well tolerated. Shown in 
Fig. 3.7 are representative H&E images of B16-F10 tumors from mice in different groups. Tumors 
in mice that were left untreated (A) or treated with vehicle (B) or DHA-dFdC-free SLNs (C) were 
in a late tumor stage with large blood vessels with large lumen. In addition, tumors in these groups 
showed large necrotic area, increase in the desmoplasia, and vascular collapse (Fig. 3.7A-C). In 
solid tumors such as melanoma, high interstitial fluid constitutes a significant barrier to 
chemotherapy as it induces the compression of blood vessels, diverting the blood from the center 
of tumors to the periphery, which reduces the transcapillary transport of chemotherapeutics (38). 
Tumor treated with DHA-dFdC-SLNs showed a higher number of blood vessels with small lumen 
(Fig. 3.7G). In addition, an increasing level of connective tissue can be observed around the 
tumoral zone in tumors in mice treated with DHA-dFdC-SLNs (Fig. 3.7F). In fact, this connective 
tissue may have tumor encapsulation effect, providing a protective barrier to tumor local and 
vascular invasion as suggested (39). For example, it was reported that patients with liver metastasis 
have a better prognostic when metastasis encapsulation occurs by the formation of a fibrotic 
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capsule (40-42). Indeed, it was suggested that the formation of capsules protects the liver 
parenchyma from cancer invasion (42). This evidence supports the use of DHA-dFdC-SLNs to 
treat melanoma, inducing the tumor encapsulation for further removal by surgery and avoiding 
metastasis due to the protective effect of this capsule. On the other hand, tumors in mice treated 
with DHA-dFdC showed vascular collapse, high desmoplasia, and necrotic areas (Fig. 3.7D-E). 
Tumors in mice treated with DHA-dFdC-SLNs shown a more cells in apoptosis, but less cells in 
necrosis, as compared to tumors in mice treated with DHA-dFdC in solution or left untreated. In 
this study, DHA-dFdC-free SLNs (i.e. Blank-SLNs) showed a tendency to delay tumor growth as 
compared to the untreated group (Fig. 3.6A). In fact, in vivo and in vitro studies reported that TPGS 
had anticancer activity as a single agent, being able to inhibit the growth of human prostate and 
lung carcinoma cells (25, 43). Furthermore, it was reported that TPGS selectively induces 
apoptosis in T cell acute lymphocytic leukemia (ALL) or Jurkat clone E6-1 cells through the 
induction of oxidative stress pathway (44). In addition, TPGS was reported to selectively induce 
cell cycle arrest and apoptosis in breast cancer cell lines such as MCF7 and MDA-MB-231, but 
not in “normal” immortalized cells such as MCF-10A and MCF-12F (45). Finally, a synergistic 
effect between TPGS2k and docetaxel was reported in MCF-7 cell lines, wherein the incubation of 
MCF-7 cells with TPGS2k micelles without docetaxel induced cytotoxicity (24). One reason that 
could explain the lack of cytotoxicity by our DHA-dFdC-free SLNs in culture cells is the low 
concentration of TPGS used in the formulation (» 1.5 mM). Indeed, higher concentrations TPGS 
were used in culture to induce cell cytotoxicity (e.g. > 10 mM), and in animal studies to suppress 




























Fig. 3.6 Antitumor activity of DHA-dFdC-SLNs against B16-F10 tumor in a mouse model. 
(A) Tumor growth curve. (B) Mouse body weight change curves. C57BL76 mice 
were s.c. injected with B16-F10 tumor on day 0. On day 7, mice were randomized 
into 5 groups (n = 5-6) and i.v. injected with DHA-dFdC-SLNs, DHA-dFdC in 
vehicle, Blank-SLNs (DHA-dFdC-free SLNs) on days 7, 10, 13, and 16. The dose of 
DHA-dFdC was 50 mg/kg. As controls, one group of mice were left untreated. Data 
shown are mean ± SEM. p < 0.05; a DHA-dFdC-SLNs vs untreated; b DHA-dFdC-
SLNs vs DHA-dFdC; c DHA-dFdC-SLNs vs Blank-SLNs; d DHA-dFdC-SLNs vs 
vehicle 
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Fig. 3.7 (A-G) Representative H&E images of B16-F10 tumors in C57BL76 mice i.v. injected 
with DHA-dFdC-SLNs, DHA-dFdC-free SLNs, DHA-dFdC in vehicle, vehicle alone 
or left untreated. Mice were euthanized on day 17 to collect tumor tissues. Tumor 
tissues of untreated (A), vehicle (B), and Blank-SLNs (C) groups are represented at 
a magnification 200X; while DHA-dFdC (D-E) and DHA-dFdC-SLNs (F-G) groups 
are represented by two different magnifications (100X (left), 200X (right)). The scale 
bars in the 100 X images represent 100 µm, and that in the 200 X images represent 
50 µm. Black circles represent tumor area, orange dashed lines represent necrotic 
area, black arrows represent apoptotic cells, asterisk represent desmoplasia, orange 
arrows represent blood vessel, times signs represent infiltration areas, black squares 




























































In summary, we report a promising SLN formulation of our DHA-dFdC. All materials used 
in the formulation are biocompatible. Indeed, lecithin, GMS, and Tween 20 are GRAS materials 
for parenteral administration (46). TPGS has been approved by the FDA as a safe pharmaceutical 
adjuvant that allows its use parenteral pharmaceutical formulations (46). Moreover, the method of 
preparing the SLN formulation is straight forward, inexpensive and potentially scalable for 
industrial manufacturing. In addition, the small size of the DHA-dFdC-SLNs (102.2 ± 7.3 nm) 
allows their sterilization by filtration (0.2 µm). Finally, toxic organic solvents were not used when 
preparing the SLNs during the emulsion preparation, avoiding the evaporation process and residual 
solvent in the formulation. As to the mechanism underlying the improved antitumor activity of the 
DHA-dFdC-SLNs in the animal model,  the enhance permeability and retention effect (EPR) was 
likely responsible (47).  
 
3.5 CONCLUSION 
We report a new solid lipid nanoparticle formulation of DHA-dFdC that significantly 
increases the water solubility and chemical stability of DHA-dFdC. The DHA-dFdC-SLNs also 
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Chapter 4: A Solid Lipid Nanoparticle Formulation Improves the Oral 




Previously, we synthesized 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-
dFdC), a novel lipophilic compound with a potent, broad spectrum antitumor activity and 
developed a solid lipid nanoparticle (SLN) formulation of the DHA-dFdC (i.e. DHA-dFdC-SLNs) 
to improve the solubility and chemical stability of DHA-dFdC. The SLNs were prepared from 
lecithin/glycerol monosterate-in-water emulsions emulsified with D-α-tocopherol polyethylene 
glycol 1000 succinate and Tween 20. Herein, we studied the feasibility of administering the DHA-
dFdC by the oral route using the SLN formulation. In simulated gastrointestinal fluids, the DHA-
dFdC-SLNs did not aggregate. Overall, the release of the DHA-dFdC from the SLNs in simulated 
gastrointestinal fluids was slow, but it was slightly faster in simulated intestinal fluid than in 
simulated gastric fluid. In mice orally gavage with DHA-dFdC-SLNs, plasma DHA-dFdC 
concentration followed a bi-exponential model, with a Tmax of ~ 1.7 h and a Cmax of 17.01 µg/mL. 
The absolute oral bioavailability of DHA-dFdC in the DHA-dFdC-SLNs was ~ 68% (based on the 
AUC0-24h values). Finally, in mice with pre-establish B16-F10 murine melanoma, oral DHA-
dFdC-SLNs increased the mouse survival significantly. It is concluded that the DHA-dFdC-SLNs 






Oral route is preferred for drug administration due to advantages such as painlessness, 
easiness for self-administration, flexibility in dosage regimen, convenience, and high patient 
compliance (1, 2). Furthermore, oral product manufacturing does not require  sterile conditions 
that are necessary for products intended for parenteral administration (1). In cancer chemotherapy, 
there are studies reported that cancer patients prefer oral administration to intravenous infusion, 
especially when chemotherapy is just a palliative treatment (2-4). However, oral administration of 
cancer chemotherapeutic agents is rather challenging, in part because the gastrointestinal (GI) tract 
presents various physiological, enzymatic and chemical barriers, hindering an efficient oral 
absorption (2, 5). In addition, factors such as low solubility, poor intestinal permeability, and high 
level of P-glycoprotein (P-gp) in the GI tract wall also limit the oral bioavailability of many cancer 
chemotherapeutic agents (e.g., paclitaxel, docetaxel, doxorrubicin, tamoxifen, etc.) (2). 
Nanocarriers (e.g. SLNs, liposomes, nanoemulsions, micelles, and polymeric nanoparticles) have 
gained attention to improve the oral delivery of anticancer drugs due to their ability to increase the 
apparent solubility of drugs, reduce the degradation of drugs within the GI tract, and improve drug 
absorption (1, 2, 5).  
Previously, we reported a new SLN formulation of DHA-dFdC, DHA-dFdC-SLNs, to 
improve the apparent solubility and stability of DHA-dFdC, a novel compound synthesized in our 
laboratory by conjugating docosahexaenoic acid at the 4-NH2 position of dFdC (2′, 2′-
difluorodeoxycytidine). DHA-dFdC shows a potent and broad-spectrum antitumor activity in vivo 
and in vitro (6). DHA-dFdC-SLNs were prepared by incorporating DHA-dFdC into SLNs prepared 
from lecithin/glycerol monostreate (GMS)-in-water emulsions emulsified with Tween 20 and D-
α-tocopherol polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS). The SLNs are 102 
± 7 nm, with a zeta potential of -55 ± 3 mV. DHA-dFdC-SLNs increase the apparent water 
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solubility and chemical stability of DHA-dFdC. In the present work, we show that the DHA-dFdC-
SLNs also enable the oral administration of DHA-dFdC.   
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Materials and cell lines 
Mannitol, Tween 20, GMS, TPGS, sodium chloride (NaCl), hydrochloric acid (HCl, 37 
%), monobasic potassium phosphate (KH2PO4), sodium hydroxide (NaOH), and Tween 80 were 
from Sigma-Aldrich (St. Louis, MO). Gemcitabine HCl was from Biotang, Inc. (Lexington, MA). 
Soy lecithin was from Alfa Aesar (Ward Hill, MA). Ethyl acetate (EtOAc), tetrahydrofuran 
(HPLC-grade), isopropanol, and methanol (HPLC-grade) were from Thermo Fisher Scientific 
(Waltham, MA). Float-A-Lyzer®G2 dialysis device (MWC 50 kD) was from Spectrum Inc. (New 
Brunswick, NJ). 
Murine melanoma (B16-F10) cancer cell lines were from the American Type Culture 
Collection (Manassas, VA). B16-F10 cells were grown in DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 μg/mL 
of streptomycin, all from Invitrogen (Carlsbad, CA).  
 
4.3.2 Synthesis of 4-(N)-docosahexaenoyl 2′,2′-difluorodeoxycytidine (DHA-dFdC) 
DHA-dFdC was synthesized following our previously reported conjugation scheme (6). 
The purity of the resultant DHA-dFdC was confirmed by NMR and Mass Spectrum analyses.  
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4.3.3 Preparation and characterization of 4-(N)-docosahexaenoyl 2′, 2′-
difluorodeoxycytidine nanoparticles (DHA-dFdC-SLNs) 
Nanoparticles were prepared as previously described (7). Briefly, 3.5 mg of soy lecithin, 
0.5 mg of GMS, 0.875 mg of TPGS, were weighed into a 7 ml glass vial. Eight hundred microliter 
of de-ionized and filtered (0.22 μm) hot water (at 80°C) was added into the lecithin/GMS/TPGS 
mixture, which was then vortexed and sonicated for 3 min until homogenous slurry was formed. 
The mixture was maintained on an 80°C hot plate for 5 min. A solution of Tween 20 (55 mg in 1 
ml of water) was prepared, and 200 μL of the solution was added drop wise into the mixture to 
reach a final concentration of 1% (v/v). The resultant emulsions were allowed to cool to room 
temperature while stirring to form nanoparticles. 
To incorporate DHA-dFdC into the nanoparticles to form DHA-dFdC-SLNs, 5.2 mg of 
DHA-dFdC was added into lecithin/GMS/TPGS mixture before the addition of water. The 
remaining steps were identical to the preparation of DHA-dFdC-free nanoparticles. The size and 
zeta potential of the nanoparticles were measured using a Malvern Zetasizer Nano ZS 
(Westborough, MA). 
DHA-dFdC was extracted from the nanoparticles to determine its concentration. Briefly, 
100 μL of DHA-dFdC-SLNs were mixed with 100 μL of isopropanol, vortexed for 30 s, and 
maintained at room temperature. Five minutes later, 600 μL of ethyl acetate was added. The 
mixture was vortexed per 30 s and centrifuged at 11,000 rcf for 20 min. The supernatant was 
collected into a glass vial. After the solvent was evaporated under nitrogen, the sample was re-
dissolved in 100 μL of THF, and the concentration of DHA-dFdC was measured by HPLC (6). 
 
4.3.4 Stability of DHA-dFdC-SLNs in stimulated gastrointestinal fluids 
The stability of DHA-dFdC-SLNs in simulated gastric fluid (SGF, pH 1.2) and simulated 
intestine fluid (SIF, pH 6.8) without enzymes was evaluated. SGF and SIF were prepared 
according USP XXVI. The SGF was prepared by dissolving 2 g of NaCl into 7 mL of HCl, and 
completed the volume to 1000 mL with deionized water (8). The SIF was prepared by adding 6.8 
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g of KH2PO4 and 896 mg NaOH into 1000 mL of deionized water (8). DHA-dFdC-SLNs were 
incubated in SGF or SIF media at 37°C under agitation (100 rpm). At different time points (i.e. 0, 
1, 2, 4, and 6 h), samples were taken and diluted into water to measure particle size using Malvern 
Zetasizer Nano ZS. As a control, DHA-dFdC-SLNs were incubated in phosphate-buffered saline 
(PBS, 10 mM, pH 7.4). The experiments were repeated three times.  
 
4.3.5 Transmission electron micrographs (TEM) 
The size and morphology of the DHA-dFdC-SLNs before and after incubation in SGF and 
SIF were examined using a transmission electron microscope available in the Institute for Cellular 
and Molecular Biology Microscope and Imaging Facility at The University of Texas at Austin. 
The carbon film-coated copper grid was glow discharged for 2 min. A sample of 10 µL of DHA-
dFdC-SLNs suspended in water was deposited on the grid and left to stand for 1 min. The sample 
excess was removed with a filter paper. One drop of 1% uranyl acetate was added on the grid for 
30 s. The sample was then observed under the TEM after removing the excess uranyl acetate fluid 
with filter paper (9). 
 
4.3.6 In vitro release in simulated gastrointestinal fluids 
To test the release behavior of DHA-dFdC from DHA-dFdC-SLNs in SGF and SIF, DHA-
dFdC-SLNs in SGF or SIF were placed into a 1 mL of cellulose ester dialysis tube (151 μg/mL of 
DHA-dFdC), which was then placed in a plastic conical tube containing 13 mL of dissolution 
media (i.e. SGF or SIF with 2.5% of Tween 20) to create a sink condition. The plastic tube was 
placed in a thermostatic shaker at 37°C at 100 rpm (Max Q 200, Thermo Fisher Scientific). At 
predetermined time points, 200 μL of the release medium was withdrawn and subsequently 
replaced with an equal volume of fresh medium. The concentration of DHA-dFdC in the medium 
was determined using HPLC. As a control, 151 μg of DHA-dFdC was dissolved in 2.5% of Tween 
 91 
20 to confirm that the diffusion of DHA-dFdC across the dialysis tube membrane was not rate-
limiting.  
 
4.3.7 Pharmacokinetic studies 
The Institutional Animal Care and Use Committee at The University of Texas at Austin 
approved the animal protocol. Female C57BL/6 mice (6-8 weeks, Charles River Laboratories, 
Wilmington, MA) were fasted for 3 h. Water was allowed ad libitum. Mice were orally gavaged 
with DHA-dFdC dissolved in a vehicle solution (i.e. Tween 80 (10%, w/v), ethanol (5.2% v/v), 
and mannitol (5%, w/v) in sterile water) (6, 10) or the DHA-dFdC-SLNs suspended in a sterile 
mannitol solution (5%, w/v), or intravenously injected with the DHA-dFdC-SLNs suspended in a 
sterile mannitol solution (5%, w/v). The dose of DHA-dFdC was 2 mg per mouse. Mice (n = 3) 
were euthanized at various time points (i.e. 0.25, 0.5, 1, 2, 5, 8, 12, and 24 h). Blood was collected 
into heparin-coated tubes, which were then centrifuged at 13,000 rcf for 20 min to isolate plasma. 
The plasma (200 μL) was mixed with 200 μL of isopropanol and 200 μL of cold PBS, vortexed 
and then incubated at 4°C for 5 min. Following incubation, 1000 μl of ethyl acetate was added. 
The mixture was vortexed for 5 min, followed by centrifugation at 18,000 rcf for 5 min. The 
supernatant was collected and dried under nitrogen. Finally, the residue was re-dissolved in 100 μl 
of THF, which was then analyzed using HPLC (6). As internal control 4-(N)-stearoyl 2′,2′-
difluorodeoxycytidine (GemC18) was added in the samples before extraction (11). Data were 
analyzed using PK Solver®, assuming a two-compartmental model (8).  
 
4.3.8 Antitumor activity of orally administered DHA-dFdC-SLNs in a tumor-bearing 
mouse model 
Female C57BL/6 mice (18-20 g) were subcutaneously (s.c) injected with B16-F10 (5 x 105 
cells/mouse) in the right flank on day 0. Seven days later, mice were randomized into 4 groups (n 
= 7-8) and orally gavaged with DHA-dFdC (250 μg/mouse) dissolved in vehicle (6, 10), DHA-
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dFdC-SLNs (250 μg/mouse of DHA) dispersed in mannitol 5%, or DHA-dFdC-free SLNs 
dispersed in mannitol 5%. As a control, one group of mice were left untreated. Treatment was 
repeated every day until day 11. Mice were allowed to rest for two days, and treatment was 
resumed on day 13 and continued until day 20. Mice were monitored daily until the endpoint (i.e. 
death, tumor size reaching 15 mm, tumor ulceration, body weight loss of more than 20%, or other 
signs of severe distress and discomfort). 
 
4.3.9 Statistical analysis 
Statistical analyses were completed by one-way ANOVA followed by a Bonferroni post 
hoc test. Mouse survival curves were compared using the Mantel-Cox log-rank method. A p value 
of ≤ 0.05 (two-tail) was considered significant. Most of the analyses were performed with 
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Pharmacokinetic parameters were 












4.4 RESULTS AND DISCUSION 
 
The use of solid-lipid nanoparticles for oral drug administration provides several 
advantages, such as improving the stability, enhancing the bioavailability of the drug and 
decreasing its toxicity (5, 13-16). Previously, we prepared DHA-dFdC-SLNs by incorporating 
DHA-dFdC into solid lipid nanoparticles prepared with soy lecithin, GMS, TPGS, and Tween 20 
to overcome its poor water solubility and chemical instability of DHA-dFdC (paper submitted) 
(6). The main characteristics of the DHA-dFdC-SLNs are summarized in Table 4.1. The size of 
the nanoparticles is 100.5 ± 7.72 nm. It is known that the particles size significantly affect the 
gastrointestinal absorption, and nanoparticles with a particle size lower than 300 nm are good 
candidate for oral administration (2, 17). Indeed, an evaluation of the cellular uptake of polymeric 
nanoparticles (i.e. Vitamin E TPGS-coated PLGA nanoparticles or PVA-coated PLGA 
nanoparticles) by Caco-2 cells in culture showed that the most desirable particles size is in the 
range of 100-200 nm (17). It was also reported that the surface properties of the nanoparticles are 
also important to improve the cellular uptake of the nanoparticles; surface modification of the 
nanoparticles with vitamin E TPGS improved considerably the cellular uptake (17). The zeta 
potential of our DHA-dFdC-SLNs is -43.5 ± 2.2 mV, indicating their stability in an aqueous 
suspension (17, 18).  
 
Table 4.1 Characterization of DHA-dFdC-SLNs. Data shown are mean ± S.D. (n = 3) 
DHA-dFdC (mg) 5.2 
Particle diameter (nm) 100.5 ± 7.72 
Polydispersity index 0.214 ± 0.03 
Zeta potential (mV) -43.5 ± 2.2 
Entrapment efficiency % 97% ± 21.4 
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4.4.1 Stability of DHA-dFdC-SLNs in stimulated gastrointestinal fluids 
Figure 4.1 shows the in vitro stability data of DHA-dFdC-SLNs in simulated 
gastrointestinal (GI) fluid (e.g. SGF or SIF). As a control, the stability of the DHA-dFdC-SLNs in 
PBS (10 mM, pH 7.4) was also included. The particles size of the DHA-dFdC-SLNs as measured 
by DLS did not increased during a 6 h of incubation in SGF or SIF. Indeed, particle size decreased 
slightly (i.e. ~5.4% in SIF and 6.1% in SGF, as compared to in PBS) (Fig. 4.1A). Shown in Fig. 
4.1B-G are representative TEM images of the nanoparticles before and after 6 h of incubation in 
SGF or SIF. Overall, the shape of the nanoparticles did not change significantly after the 
incubation; however, after 6 h of incubation in SIF, the surface of the DHA-dFdC-SLNs appears 
rough (Fig. 4.1E, inset), which is not the case after the DHA-dFdC-SLNs were incubated in the 
SGF (Fig. 4.1G, inset). Studies examining the degradation of SLNs in GI fluids showed that their 
degradation induces a decrease in particle size due to the loss of surfactant coated on the surface 
of the nanoparticles, which ultimately led to an increase in the particle size of SLNs, because the 
nanoparticles aggregate in the absence of surfactant (18, 19). It was reported that non-ionic 
surfactants such as Tween 80, Tween 20, Tween 60, and PVA provide steric stabilization to 
particles in acid pH (20). Tween 20 was used as a surfactant in the DHA-dFdC-SLNs, which might 
explain the stability of them in the SGF. TPGS is a non-ionic surfactant as well, and the presence 
of TPGS in our DHA-dFdC-SLNs may have also contributed to the stability of the nanoparticles 
in simulated GI fluids. It is worth noting that the SGF and SIF we used in the stability studies did 































Fig. 4.1 Stability of DHA-dFdC-SLNs in simulated gastrointestinal fluids. A. Stability of 
DHA-dFdC-SLNs after 6 DHA-dFdC-SLNs were incubated with SGF (pH 1.2) or 
SIF (pH 6.8) at 37°C. Samples were collected at 0, 1, 2, 4 and 6 h to measure the 
particle size. As a control, DHA-dFdC-SLNs were also incubated with PBS. Data are 
expressed as mean ± SD (n = 3). B-G. Representative TEM images of DHA-dFdC-
SLNs incubated with PBS (B-C at 0 and 6 h, respectively), SIF (D-E at 0 and 6 h, 
respectively), and SGF (F-G at 0 and 6 h, respectively). Bar = 500 nm 















































































4.4.2 In vitro release in simulated gastrointestinal fluids 
The in vitro release profiles of DHA-dFdC from the DHA-dFdC-SLNs in simulated GI 
fluids are shown in Fig. 4.2. After 6 h, the cumulative release of DHA-dFdC reached ~ 8.9% and 
~ 3.2% in SIF and SIG, respectively. Similar to the stability study mentioned above, the release of 
DHA-dFdC from the DHA-dFdC-SLNs was monitored for 6 h only, because there is report that 
the GI transition time in mice is 6-8 h (21). As shown in Fig. 4.1E insert, the surface of the SLNs 
is not smooth after 6 h of incubation in SIF, indicting erosion of the particles, which may explain 













Fig. 4.2 In vitro release profiles of DHA-dFdC from DHA-dFdC-SLNs in simulated 
gastrointestinal fluids. As controls, the diffusion of DHA-dFdC (in DHA-dFdC-in 
Tween 20 micelles) across the dialysis membrane was also monitored. Data are 
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4.4.3 Oral bioavailability of DHA-dFdC in DHA-dFdC-SLNs 
The plasma concentrations of DHA-dFdC at different time points after oral administration 
or intravenous injection of the DHA-dFdC-SLNs in suspension at 2 mg of DHA-dFdC per mouse 
are shown in Fig. 4.3. Selected pharmacokinetic parameters of DHA-dFdC are summarized in 












 Plasma DHA-dFdC concentration-time curves after oral administration of DHA-
dFdC-SLNs in suspension or DHA-dFdC in Tween 20-ethanol-water solution, or i.v. 
administration of DHA-dFdC-SLNs in suspension in healthy C57BL/6 mice. The 
dose of DHA-dFdC was 2 mg per mouse. Data are expressed as mean ± S.D. (n = 3)























Table 4.2 Selected pharmacokinetics parameters of DHA-dFdC in plasma followed by i.v. administration of DHA-dFdC-SLNs oral 












Abbreviations: AUC, total area under the plasma concentration-time curve form time zero to 24 h; Cmax, peak plasma 




Oral administration i.v. administration 
DHA-dFdC-SLNs DHA-dFdC DHA-dFdC-SLNs 
Dose (mg) 2 2 2 
k12 (1/h) 0.41 0.56 0.40 
T 1/2 a (h) 1.10 1.07 0.53 
T ½ b (h) 32.76 693147.18 25.58 
Tmax (h) 1.73 1.75 - 
Cmax (µg/mL) 17.01 10.50 - 
AUC0-24 (µg*h/mL)  143.44 113.55 210.58 
Fab% 68.12 - - 
Frel% 126.32 - - 
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The plasma DHA-dFdC level after i.v. administration of DHF-dFdC-SLNs in healthy mice 
appeared to follow a two-compartment model with AUC0-24h value of 210.58 µg*h/mL. On the 
other hand, the plasma DHA-dFdC level in mice after oral administration of DHA-dFdC-SLNs 
followed an apparent adsorption phase and then a clearance phase, with a Cmax of 17.01 µg/mL, 
Tmax of 1.73 h, and AUC0-24h of 143.44 µg*h/mL. The absolute oral bioavailability of DHA-dFdC 
in the DHA-dFdC-SLNs was calculated to be 68.12% based on the AUC0-24h values shown in 
Table 4.2.  
For a comparison, the plasma concentration of DHA-dFdC-time curve of the DHA-dFdC 
after it was oral administered in a Tween 80-ethanol-water solution is also showed in Fig. 4.3. The 
Tmax was ~1.7 h, similar to that of the oral DHA-dFdC in SLNs (Table 4.2). However, the Cmax 
and AUC0-24h values of the DHA-dFdC in solution were found to be 10.50 µg/mL and 113.55 
µg*h/mL, respectively. Therefore, the bioavailability of DHA-dFdC in the DHA-dFdC-SLNs, 
relative to in the Tween 80-ethanol in water solution was 126.4%. 
The exact mechanism by which the DHA-dFC in the DHA-dFdC-SLNs was absorbed into 
the blood circulation after oral gavage is unknown. In general, orally administered SLNs can be 
absorbed as intact particles through the microfold cells in the Peyer´s patches and then transported 
to the lymphatic system (22). However, others suggested that SLNs suffer from digestion or 
degradation in the GI tract, and only a very small fraction, if any, of orally administered SLNs can 
reach the blood circulation intact (23). Of course, DHA-dFdC can be released from the SLNs in 
the GI tract (Fig. 4.2), especially in the presence of lipases and co-lipases from pancreas, and then 
absorbed by passive diffusion or with the help of bile in the GI tract (24, 25).  
As to the higher bioavailability of DHA-dFdC in SLNs relative to DHA-dFdC in Tween 
80/ethanol/water solution, the DHA-dFdC in the solution may be susceptible to precipitation when 
orally administered, which can lead to a decrease in its bioavailability (6). It is also thought that 
the higher levels of exogenous lipids from SLNs after digestion (i.e. exogenous solubilizing 
components), relative to endogenous solubilizing components in the GI tract, may lead to a change 
in the nature of the GI fluid and enhance DHA-dFdC solubilization (25). Nonetheless, since the 
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solution of DHA-dFdC contains Tween 80, which may explain the relatively high oral 
bioavailability of DHA-dFdC in the solution (26). Tween 80 can be digested by intestinal cells to 
release oleic acid, which is used to increase the basolateral secretion of triglyceride-rich 
lipoproteins such as chylomicrons, increasing the lymphatic uptake of lipophilic drug (26). In 
addition, Tween 80 can inhibit intestinal P-gp efflux, increasing the concentration and residence 
time into the enterocyte of P-gp substrate (27). Although Tween 80 can inhibit intestinal P-gp 
activity, it is least effective than TPGS (28). It was reported that TGPS as emulsifier in a paclitaxel-
polymeric nanoparticle formulation helped to increase the oral bioavailability of paclitaxel by 10-
fold, as compared to oral Taxol (21). Furthermore, it was reported that TPGS1000-emulsified 
SLNs improved the intestinal absorption and relative oral bioavailability of docetaxel in rats (29). 
Therefore, the high oral bioavailability of DHA-dFdC in our DHA-dFdC-SLNs may be attributed 
in part to the presence of TPGS in the formulation as well. 
 
4.4.4 Antitumor activity of DHA-dFdC-SLNs in a tumor-bearing mouse model 
The antitumor activity of DHA-dFdC-SLNs was evaluated in a mouse melanoma model. 
Previously, we reported that DHA-dFdC-SLNs significantly inhibit the growth of B16-F10 tumor 
cells in culture and in mice when given intravenously. Consequently, we chose to use B16-F10 
tumor-bearing mice to test the antitumor activity of DHA-dFdC-SLNs when given orally. DHA-
dFdC-SLNs were orally gavaged at a dose of 250 µg of DHA-dFdC per mouse daily for a total of 
12 days (with a two-day rest in the middle). As shown in Fig. 4.4, 50% of mice in the untreated 
group reached the endpoint on day 16. Oral DHA-dFdC-SLNs significantly improved the survival, 
as compared to the untreated group (p < 0.05). Oral DHA-dFdC in Tween 80/ethanol/water 
solution did not significantly affect mouse survival as compared to mice left untreated, which is 
surprising because the bioavailability of the DHA-dFdC in the Tween 80/ethanol/water solution 
was ~54% (Table 4.2). Toxicity associated with the DHA-dFdC in Tween 80/ethanol/water 
solution was likely related to the lack of survival advantage of the DHA-dFdC solution over 
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untreated mice, as 62.5% of the mice orally gavaged with the DHA-dFdC in Tween 
80/ethanol/water solution showed signs of toxicity such as a body weight decrease of more than 
20% (i.e. one mouse) or severe tumor ulceration (i.e. four mice). The exact reasons underlying the 
toxicity of the DHA-dFdC in the Tween 80/ethanol-water solution remains unknown, but should 
be related to the Tween 80-ethanol-water solution, although the amounts of Tween 80 and ethanol 
taken by mice from the DHA-dFdC in Tween 80/ethanol/water solution were within the normal 
range recommended for preclinical animal study (i.e. water with not over 10% Tween 80 and 5% 
solution of ethanol for one month is well tolerated) (30, 31). Nonetheless, the mouse survival data 











Fig. 4.4  Survival curves of B16-F10 tumor-bearing mice after oral treatment with DHA-
dFdC-SLNs. Tumor cells were injected (s.c.) on day 0. On day 7, mice were 
randomized and orally gavaged with DHA-dFdC-SLNs in suspension or DHA-dFdC 
in a Tween 80-ethanol in water solution. As controls, mice received DHA-dFdC-free 
SLNs (blank-SLNs) or left untreated. * p < 0.05, DHA-dFdC-SLNs vs. all other 




























In the present study, we reported that it is feasible to orally administer DHA-dFdC using 
DHA-dFdC-SLNs. The oral bioavailability of DHA-dFdC in the DHA-dFdC-SLNs was ~68%, 
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Chapter 5: General Conclusion 
 
 
DHA-dFdC is a novel compound synthesized by conjugating DHA and dFdC in the 4’-N 
position. DHA-dFdC has potent, broad spectrum antitumor activity. In this dissertation, we tested 
the toxicity of DHA-dFdC dissolved in a Tween 80-ethanol-water solution and developed a solid-
lipid nanoparticle formulation of DHA-dFdC (i.e. DHA-dFdC-SLNs) that improves the water 
solubility and chemical stability of DHA-dFdC. In addition, this formulation modifies the plasma 
pharmacokinetic parameters of DHA-dFdC after intravenous or oral administration. Finally, DHA-












Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, Ramírez-Vick JE. 
Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on 
MCF7 cells. Drug delivery. 2013;20(8):338-348. 
 
Aditya N, Shim M, Lee I, Lee Y, Im M-H, Ko S. Curcumin and genistein coloaded 
nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. 
Journal of agricultural and food chemistry. 2013;61(8):1878-1883. 
 
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, 
Melemed AS, Reyes-Vidal JM, Sekhon JS. Gemcitabine plus paclitaxel versus 
paclitaxel monotherapy in patients with metastatic breast cancer and prior 
anthracycline treatment. Journal of Clinical Oncology. 2008;26(24):3950-3957. 
 
Alex MA, Chacko A, Jose S, Souto E. Lopinavir loaded solid lipid nanoparticles (SLN) for 
intestinal lymphatic targeting. European Journal of Pharmaceutical Sciences. 
2011;42(1-2):11-18. 
 
Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, 
Schiavon O, Summerford C, Tirk A, Veronese FM, Vincenzi V, Wu G. 
Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-
peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer 
conjugates. Biomacromolecules. 2005;6(2):914-926. 
 
Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, 
Goldin RD. Impact of pan-caspase inhibition in animal models of established 
steatosis and non-alcoholic steatohepatitis. Journal of hepatology. 2010;53(3):542-
550. 
 
Arshad A, Chung WY, Steward W, Metcalfe MS, Dennison AR. Reduction in circulating 
pro-angiogenic and pro-inflammatory factors is related to improved outcomes in 
patients with advanced pancreatic cancer treated with gemcitabine and intravenous 
omega-3 fish oil. HPB (Oxford). 2013;15(6):428-432. 
 
 108 
Arshad A, Isherwood J, Mann C, Cooke J, Pollard C, Runau F, Morgan B, Steward W, 
Metcalfe M, Dennison A. Intravenous omega-3 Fatty Acids Plus Gemcitabine: 
Potential to Improve Response and Quality of Life in Advanced Pancreatic Cancer. 
JPEN J Parenter Enteral Nutr. 2015. 
 
Assanhou AG, Li W, Zhang L, Xue L, Kong L, Sun H, Mo R, Zhang C. Reversal of 
multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and 
hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials. 
2015;73:284-295. 
 
Arterburn LM, Boswell KD, Koskelo E, Kassner SL, Kelly C, Kyle DJ. A combined 
subchronic (90-day) toxicity and neurotoxicity study of a single-cell source of 
docosahexaenoic acid triglyceride (DHASCO oil). Food Chem Toxicol. 
2000;38:35–49.  
 
Bazak R, Houri M, El Achy S, Hussein W, Refaat T. Passive targeting of nanoparticles to 
cancer: A comprehensive review of the literature. Molecular and clinical oncology. 
2014;2(6):904-908. 
 
Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, 
Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, 
Vaid RK, Zhang D, McCarthy JR. Synthesis, Crystallization, and Biological 
Evaluation of an Orally Active Prodrug of Gemcitabine. Journal of Medicinal 
Chemistry. 2009;52(22):6958-6961. 
 
Bergman AM, Eijk PP, Ruiz van Haperen VWT, Smid K, Veerman G, Hubeek I, van den 
IJssel P, Ylstra B, Peters GJ. <em>In vivo</em> Induction of Resistance to 
Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit 
M1 as the Major Determinant. Cancer Research. 2005;65(20):9510-9516. 
 
Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′, 2′-
difluorodeoxycytidine (gemcitabine). Drug resistance updates. 2002;5(1):19-33. 
 
Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander 
MC, Baker SD, He L, Horwitz SB. Tumor targeting by covalent conjugation of a 
natural fatty acid to paclitaxel. Clinical Cancer Research. 2001;7(10):3229-3238. 
 109 
 
Brusa P, Immordino ML, Rocco F, Cattel L. Antitumor activity and pharmacokinetics of 
liposomes containing lipophilic gemcitabine prodrugs. Anticancer research. 
2007;27(1A):195-199. 
 
Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps 
MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, 
Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as 
first-line therapy for patients with advanced pancreas cancer: a randomized trial. J 
Clin Oncol. 1997;15(6):2403-2413. 
 
Camargo Cde Q, Mocellin MC, Pastore Silva Jde A, Fabre ME, Nunes EA, Trindade EB. 
Fish oil supplementation during chemotherapy increases posterior time to tumor 
progression in colorectal cancer. Nutr Cancer. 2016;68(1):70-76. 
 
Carini R, Poli G, Dianzani MU, Maddix SP, Slater TF, Cheeseman KH. Comparative 
evaluation of the antioxidant activity of α-tocopherol, α-tocopherol polyethylene 
glycol 1000 succinate and α-tocopherol succinate in isolated hepatocytes and liver 
microsomal suspensions. Biochemical pharmacology. 1990;39(10):1597-1601. 
 
Carmichael J, Fink U, Russell R, Spittle M, Harris A, Spiessi G, Blatter J. Phase II study 
of gemcitabine in patients with advanced pancreatic cancer. British journal of 
cancer. 1996;73(1):101-105. 
 
Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski 
B, Tarassoff PG. Phase II trial of gemcitabine (2, 2′-difiuorodeoxycytidine) in 
patients with adenocarcinoma of the pancreas. Investigational new drugs. 
1994;12(1):29-34. 
 
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles 
(SLN) as ocular delivery system for tobramycin. International journal of 
pharmaceutics. 2002;238(1-2):241-245. 
 
Chamras H, Ardashian A, Heber D, Glaspy JA. Fatty acid modulation of MCF-7 human 




Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells 
after treatment with gemcitabine. Journal of Gastrointestinal Surgery. 
2004;8(8):1072-1078. 
 
Cho H-J, Park JW, Yoon I-S, Kim D-D. Surface-modified solid lipid nanoparticles for oral 
delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. 
International journal of nanomedicine. 2014;9:495. 
 
Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane 
transporters in cellular resistance to anticancer nucleoside drugs. In. Clinically 
Relevant Resistance in Cancer Chemotherapy: Springer; 2002. p. 27-47. 
 
Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, Garcia-Peris P, Garcia-de-Lorenzo A, 
Zarazaga A, Quecedo L, del Llano J, Usan L, Casimiro C. N-3 fatty acids, cancer 
and cachexia: a systematic review of the literature. Br J Nutr. 2007;97(5):823-831. 
 
Constantinou C, Neophytou C, Vraka P, Hyatt J, Papas K, Constantinou A. Induction of 
DNA damage and caspase-independent programmed cell death by vitamin E. 
Nutrition and cancer. 2012;64(1):136-152. 
 
Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, 
Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy 
in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine 














Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaële D, Lepêtre-Mouelhi S, Pili 
B, Bourgaux C, Amenitsch H, Ollivon M. Discovery of new hexagonal 
supramolecular nanostructures formed by squalenoylation of an anticancer 
nucleoside analogue. Small. 2008;4(2):247-253. 
 
Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi 
S, Rocco F, Dereuddre-Bosquet N, Clayette P, Rosilio V, Marsaud V, Renoir J-M, 
Cattel L. Squalenoyl nanomedicines as potential therapeutics. Nano letters. 
2006;6(11):2544-2548. 
 
Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a 
century of cancer chemotherapy. Frontiers in Pharmacology. 2013;4(68). 
 
D'Eliseo D, Manzi L, Merendino N, Velotti F. Docosahexaenoic acid inhibits invasion of 
human RT112 urinary bladder and PT45 pancreatic carcinoma cells via down-
modulation of granzyme B expression. J Nutr Biochem. 2012;23(5):452-457. 
 
Dalpiaz A, Contado C, Mari L, Perrone D, Pavan B, Paganetto G, Hanuskovà M, Vighi E, 
Leo E. Development and characterization of PLGA nanoparticles as delivery 
systems of a prodrug of zidovudine obtained by its conjugation with 
ursodeoxycholic acid. Drug delivery. 2014;21(3):221-232. 
 
Daman Z, Ostad S, Amini M, Gilani K. Preparation, optimization and in vitro 
characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its 
self-assembled nanoparticles. International journal of pharmaceutics. 2014;468(1-
2):142-151. 
 
Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active 
tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of controlled 
release. 2010;148(2):135-146. 
 
Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and 
state-of-the-art. Journal of Controlled Release. 2016;240:504-526. 
 
 112 
de Sousa Cavalcante L, Monteiro G. Gemcitabine: Metabolism and molecular mechanisms 
of action, sensitivity and chemoresistance in pancreatic cancer. European Journal 
of Pharmacology. 2014;741:8-16. 
 
Department of Health and Human Services UFaDA. Substances affirmed as generally 
recognized as safe: menhaden oil. In. Washington: Food and Drug 
Administration,HHS.; 1997. p. 30751 -30757. 
 
do Vale Morais AR, do Nascimento Alencar É, Júnior FHX, de Oliveira CM, Marcelino 
HR, Barratt G, Fessi H, do Egito EST, Elaissari A. Freeze-drying of emulsified 
systems: A review. International journal of pharmaceutics. 2016;503(1-2):102-114. 
 
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the 
M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma 
chemosensitivity to gemcitabine. Oncogene. 2004;23(8):1539. 
 
Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, Shields AL. Patient-reported 
preferences for oral versus intravenous administration for the treatment of cancer: 
a review of the literature. Patient preference and adherence. 2016;10:1609. 
Engin K, Leeper D, Cater J, Thistlethwaite A, Tupchong L, McFarlane J. Extracellular pH 
distribution in human tumours. International Journal of Hyperthermia. 
1995;11(2):211-216. 
 
Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, 
Macdonald J, Cass CE. Human equilibrative nucleoside transporter 1 levels predict 
response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 
2009;136(1):187-195. 
 
Federico C, Morittu VM, Britti D, Trapasso E, Cosco D. Gemcitabine-loaded liposomes: 
rationale, potentialities and future perspectives. International journal of 
nanomedicine. 2012;7:5423. 
 
Fendler JH, Romero A. Liposomes as drug carriers. Life Sciences. 1977;20(7):1109-1120. 
 
Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. 
Cancer letters. 2013;334(2):157-175. 
 113 
 
Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H. Nonclinical vehicle use in studies 
by multiple routes in multiple species. International journal of toxicology. 
2006;25(6):499-521. 
 
Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, Gallarate M, Dosio F. 
Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. 
European Journal of Pharmaceutics and Biopharmaceutics. 2014;87(3):433-444. 
 
Gemzar ® (gemcitabine) [package insert]. Eli Lilly and Company, IN, USA. 1996. 
Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s077lbl.pdf 
Accessed July 2, 2018. 
 
Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: 
composition, properties and therapeutic strategies. Materials Science and 
Engineering: C. 2016;68:982-994. 
 
Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R. HPMA copolymer 
platinates as novel antitumour agents: in vitro properties, pharmacokinetics and 
antitumour activity in vivo. Eur J Cancer. 1999;35(6):994-1002. 
 
Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. 
Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes. 
1996;1286(3):153-181. 
 
Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of Vitamin E TPGS in drug 
delivery. European Journal of Pharmaceutical Sciences. 2013;49(2):175-186. 
 
Gupta A, Asthana S, Konwar R, Chourasia M. An insight into potential of nanoparticles-
assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug: a 
comparative study. Journal of biomedical nanotechnology. 2013;9(5):915-925. 
 
Habiro A, Tanno S, Koizumi K, Izawa T, Nakano Y, Osanai M, Mizukami Y, Okumura T, 
Kohgo Y. Involvement of p38 mitogen-activated protein kinase in gemcitabine-
 114 
induced apoptosis in human pancreatic cancer cells. Biochemical and Biophysical 
Research Communications. 2004;316(1):71-77. 
 
Hall R, Everds N. Principles of Clinical Pathology for Toxicology Studies. In. Principles 
and Methods of Toxicology, Fifth Edition: CRC Press; 2007. p. 1317-1358. 
 
Haqq J, Howells LM, Garcea G, Dennison AR. Targeting pancreatic cancer using a 
combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, 
Lipidem. Mol Nutr Food Res. 2016;60(6):1437-1447. 
 
He K, Xun P, Brasky TM, Gammon MD, Stevens J, White E. Types of fish consumed and 
fish preparation methods in relation to pancreatic cancer incidence: the VITAL 
Cohort Study. Am J Epidemiol. 2013;177(2):152-160. 
 
Heller AR, Rossel T, Gottschlich B, Tiebel O, Menschikowski M, Litz RJ, Zimmermann 
T, Koch T. Omega-3 fatty acids improve liver and pancreas function in 
postoperative cancer patients. Int J Cancer. 2004;111(4):611-616. 
 
Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, Quisumbing M, Shapiro G, 
Witte R, Schiller JH. Phase II study of second-line gemcitabine in sensitive or 
refractory small cell lung cancer. Lung cancer. 2003;42(1):97-102. 
 
Hodge L, Taub M, Tracy T. Effect of its deaminated metabolite, 2′, 2′-
difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. 
Biochemical pharmacology. 2011;81(7):950-956. 
 
Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on 
COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. 
Carcinogenesis. 2007;28(4):809-815. 
 
Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of 




Hu X, Fan W, Yu Z, Lu Y, Qi J, Zhang J, Dong X, Zhao W, Wu W. Evidence does not 
support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale. 
2016;8(13):7024-7035. 
 
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′, 2′-
difluorodeoxycytidine on DNA synthesis. Cancer research. 1991;51(22):6110-
6117. 
 
Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, 
characterization, cytotoxicity and pharmacokinetics of liposomes containing 
lipophilic gemcitabine prodrugs. Journal of Controlled Release. 2004;100(3):331-
346. 
 
Institute NC. Cancer Treatment. Available at: https://www.cancer.gov/about-
cancer/treatment/types. Accessed July 5, 2018. 
 
Irby D, Du C, Li F. Lipid–drug conjugate for enhancing drug delivery. Molecular 
pharmaceutics. 2017;14(5):1325-1338. 
 
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: 
a cancer journal for clinicians. 2008;58(2):71-96. 
 
Jordheim LP, Dumontet C. Review of recent studies on resistance to cytotoxic 
deoxynucleoside analogues. Biochimica et Biophysica Acta (BBA)-Reviews on 
Cancer. 2007;1776(2):138-159. 
 
Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Dietary docosahexaenoic acid and 
immunocompetence in young healthy men. Lipids. 1998;33(6):559-566. 
 
Kim C, Hsieh Y-L. Wetting and absorbency of nonionic surfactant solutions on cotton 
fabrics. Colloids and Surfaces A: Physicochemical and engineering aspects. 
2001;187:385-397. 
 
Klek S. Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current 
Evidence. J Clin Med. 2016;5(3). 
 116 
 
Klijn J, Berns P, Schmitz P, Foekens J. The clinical significance of epidermal growth factor 
receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine 
reviews. 1992;13(1):3-17. 
 
Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-
Ribas I, Callies S, Benhadji KA, Slapak CA. Phase I study of oral gemcitabine 
prodrug (LY2334737) alone and in combination with erlotinib in patients with 
advanced solid tumors. Clinical cancer research. 2011;17(18):6071-6082. 
 
LeMaistre CF, Meneghetti C, Howes L, Osborne C. Targeting the EGF receptor in breast 
cancer treatment. Breast cancer research and treatment. 1994;32(1):97-103. 
 
Li F, Snow-Davis C, Du C, Bondarev ML, Saulsbury MD, Heyliger SO. Preparation and 
Characterization of Lipophilic Doxorubicin Pro-drug Micelles. Journal of 
visualized experiments: JoVE. 2016(114). 
 
Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of 
quercetin by solid lipid nanoparticles. Journal of Controlled Release. 
2009;133(3):238-244. 
 
Li J, Cheng X, Chen Y, He W, Ni L, Xiong P, Wei M. Vitamin E TPGS modified liposomes 
enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro 
evaluation. International journal of pharmaceutics. 2016;512(1):262-272. 
 
Li S, Qin J, Tian C, Cao J, Fida G, Wang Z, Chen H, Qian Z, Chen WR, Gu Y. The targeting 
mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced 
tumor therapy. Oncotarget. 2014;5(11):3622-3635. 
 
Lim S-J, Lee M-K, Kim C-K. Altered chemical and biological activities of all-trans retinoic 
acid incorporated in solid lipid nanoparticle powders. Journal of controlled release. 
2004;100(1):53-61. 
 
Lin C-H, Chen C-H, Lin Z-C, Fang J-Y. Recent advances in oral delivery of drugs and 
bioactive natural products using solid lipid nanoparticles as the carriers. Journal of 
food and drug analysis. 2017;25(2):219-234. 
 117 
 
Lippacher A, Müller R, Mäder K. Semisolid SLN™ dispersions for topical application: 
influence of formulation and production parameters on viscoelastic properties. 
European journal of pharmaceutics and biopharmaceutics. 2002;53(2):155-160. 
 
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous 
palliative chemotherapy. Journal of Clinical Oncology. 1997;15(1):110-115. 
 
Liu Y, Wang P, Sun C, Zhao J, Du Y, Shi F, Feng N. Bioadhesion and enhanced 
bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral 
delivery of poorly water-soluble drug bufalin. International Journal of 
Pharmaceutics. 2011;419(1):260-265. 
Lunevicius R, Nakanishi H, Ito S, Kozaki K-i, Kato T, Tatematsu M, Yasui K. 
Clinicopathological significance of fibrotic capsule formation around liver 
metastasis from colorectal cancer. Journal of cancer research and clinical oncology. 
2001;127(3):193-199. 
 
Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. 
Functional nucleoside transporters are required for gemcitabine influx and 
manifestation of toxicity in cancer cell lines. Cancer research. 1998;58(19):4349. 
 
MacNeill A. Clinical Biochemistry of Domestic Animals, 6th Edition by Editors: J. Jerry 
Kaneko, John W. Harvey, and Michael L. Bruss. Veterinary Clinical Pathology. 
2009;38(4):545. 
 
Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, 
Salmon I, Devière J. Human equilibrative nucleoside transporter 1 and human 
concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine 
therapy in resected pancreatic adenocarcinoma. Clinical cancer research. 
2009;15(8):2913-2919. 
 
Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. 
Materials Science and Engineering: C. 2016;60:569-578. 
 
 118 
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the 
antitumor agent smancs. Cancer research. 1986;46(12 Part 1):6387-6392. 
 
Merendino N, Costantini L, Manzi L, Molinari R, D'Eliseo D, Velotti F. Dietary omega -3 
polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. 
Biomed Res Int. 2013;2013:310186. 
Mero A, Clementi C, Veronese FM, Pasut G. Covalent conjugation of poly (ethylene 
glycol) to proteins and peptides: strategies and methods. In. Bioconjugation 
Protocols: Springer; 2011. p. 95-129. 
 
Mi Y, Liu Y, Feng S-S. Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl 
polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and 
synergistic chemotherapy. Biomaterials. 2011;32(16):4058-4066. 
 
Montgomery CA. Oncological and toxicological research: Alleviation and control of pain 
and distress in laboratory animals. Cancer Bulletin. 1990;42:230-237. 
 
Moog R, Burger A, Brandl M, Schüler J, Schubert R, Unger C, Fiebig H, Massing U. 
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in 
human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer 
chemotherapy and pharmacology. 2002;49(5):356-366. 
 
Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, 
Togo S, Danenberg PV. Human equilibrative nucleoside transporter 1 is associated 
with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and 
biliary tract carcinoma cells. Oncology reports. 2007;17(5):1201-1205. 
 
Morino T, Tanaka J, Tobe T. Clinico-pathological features of liver metastases from 
colorectal cancer in relation to prognosis. 1991. 
 
Mosallaei N, Mahmoudi A, Ghandehari H, Yellepeddi VK, Jaafari MR, Malaekeh-Nikouei 
B. Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): 
Preparation, characterization, in vitro, and in vivo evaluations. European Journal of 
Pharmaceutics and Biopharmaceutics. 2016;104:42-50. 
 
 119 
Moysan E, Bastiat G, Benoit J-P. Gemcitabine versus modified gemcitabine: a review of 
several promising chemical modifications. Molecular pharmaceutics. 
2012;10(2):430-444. 
 
Mu L, Feng S. A novel controlled release formulation for the anticancer drug paclitaxel 
(Taxol®): PLGA nanoparticles containing vitamin E TPGS. Journal of controlled 
release. 2003;86(1):33-48. 
Mu L, Feng S-S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction 
technique for fabrication of polymeric nanospheres for controlled release of 
paclitaxel (Taxol®). Journal of Controlled Release. 2002;80(1):129-144. 
 
Müller RH, MaÈder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug 
delivery–a review of the state of the art. European journal of pharmaceutics and 
biopharmaceutics. 2000;50(1):161-177. 
 
Müller RH, Rühl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function 
of lipase incubation time. International journal of pharmaceutics. 1996;144(1):115-
121 
 
Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. 
Supplementation with fish oil increases first-line chemotherapy efficacy in patients 
with advanced nonsmall cell lung cancer. Cancer. 2011;117(16):3774-3780. 
 
Muthu MS, Kulkarni SA, Xiong J, Feng S-S. Vitamin E TPGS coated liposomes enhanced 
cellular uptake and cytotoxicity of docetaxel in brain cancer cells. International 
journal of pharmaceutics. 2011;421(2):332-340. 
 
Naguib YW, Lansakara PD, Lashinger LM, Rodriguez BL, Valdes S, Niu M, Aldayel AM, 
Peng L, Hursting SD, Cui Z. Synthesis, Characterization, and In Vitro and In Vivo 
Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent 
and Broad-Spectrum Antitumor Activity. Neoplasia. 2016;18(1):33-48. 
 
Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams III RO, Cui Z. Solid lipid 
nanoparticle formulations of docetaxel prepared with high melting point 




Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, 
Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular 
markers associated with gemcitabine transport and metabolism in human pancreatic 
cancer cells. British Journal Of Cancer. 2007;96:457. 
 
Nelson GJ, Schmidt PC, Bartolini GL, Kelley DS, Kyle D. The effect of dietary 
docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in 
humans. Lipids. 1997;32(11):1137-1146. 
 
Nelson GJ, Schmidt PS, Bartolini GL, Kelley DS, Kyle D. The effect of dietary 
docosahexaenoic acid on platelet function, platelet fatty acid composition, and 
blood coagulation in humans. Lipids. 1997;32(11):1129-1136. 
 
Neophytou CM, Constantinou C, Papageorgis P, Constantinou AI. D-alpha-tocopheryl 
polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis 
selectively in Survivin-overexpressing breast cancer cells. Biochemical 
pharmacology. 2014;89(1):31-42. 
 
Nerurkar MM, Burton PS, Borchardt RT. The Use of Surfactants to Enhance the 
Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically 
Polarized Efflux System. Pharmaceutical Research. 1996;13(4):528-534. 
 
Ng IO, Lai E, Fan ST, Ng MM. Tumor encapsulation in hepatocellular carcinoma. A 
pathologic study of 189 cases. Cancer. 1992;70(1):45-49. 
 
NRC. The Guide for the Care and Use of Laboratory Animals. Washington, D.C: National 
Academies Press; 2011. 
 
Ohlsson B, Stenram U, Tranberg K-G. Resection of colorectal liver metastases: 25-year 
experience. World journal of surgery. 1998;22(3):268-277. 
 
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K. Ribonucleotide 
reductase subunit M1 is a possible chemoresistance marker to gemcitabine in 
biliary tract carcinoma. Oncology reports. 2008;20(2):279-286. 
 121 
 
Oliver S AG, Smith JE, Kaneko JJ. Erythrocyte Structure and Function. In: Douglas J. 
Weiss KJW, editor. Schalm's Veterinary Hematology. Ames: John Wiley & Sons; 
2010. p. 123-130. 
 
Ozols RF. Gemcitabine and carboplatin in second-line ovarian cancer. In.Seminars in 
oncology: Elsevier; 2005. p. 4-8. 
 
Pandey R, Sharma S, Khuller G. Oral solid lipid nanoparticle-based antitubercular 
chemotherapy. Tuberculosis. 2005;85(5-6):415-420. 
 
Park Y, Harris W. EPA, but not DHA, decreases mean platelet volume in normal subjects. 
Lipids. 2002;37(10):941-946. 
 
Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, 
characterization, and dosage form design. AAPS PharmSciTech. 2012;13(1):125-
133. 
 
Pautu V, Leonetti D, Lepeltier E, Clere N, Passirani C. Nanomedicine as a potent strategy 
in melanoma tumor microenvironment. Pharmacological research. 2017. 
 
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug 
nanocarriers, the future of chemotherapy. European journal of pharmaceutics and 
biopharmaceutics. 2015;93:52-79. 
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart 
G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck 
HJ, Rochon J, Zimmermann AH, Eisenhauer E. Gemcitabine plus carboplatin 
compared with carboplatin in patients with platinum-sensitive recurrent ovarian 
cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC 
GCG. J Clin Oncol. 2006;24(29):4699-4707. 
 
Podgorski I, Sloane BF. Cathepsin B and its role (s) in cancer progression. In.Biochemical 
Society Symposia: London; Portland on behalf of The Biochemical Society; 1999; 
2003. p. 263-276. 
 
 122 
Pooja D, Kulhari H, Kuncha M, Rachamalla SS, Adams DJ, Bansal V, Sistla R. Improving 
efficacy, oral bioavailability, and delivery of paclitaxel using protein-grafted solid 
lipid nanoparticles. Molecular pharmaceutics. 2016;13(11):3903-3912. 
 
Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing 
the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery. 
2007;6(3):231. 
 
Prabhu S, Ortega M, Ma C. Novel lipid-based formulations enhancing the in vitro 
dissolution and permeability characteristics of a poorly water-soluble model drug, 
piroxicam. International Journal of Pharmaceutics. 2005;301(1):209-216. 
 
Raabe BM, Artwohl JE, Purcell JE, Lovaglio J, Fortman JD. Effects of weekly blood 
collection in C57BL/6 mice. J Am Assoc Lab Anim Sci. 2011;50(5):680-685. 
 
Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside 
transporter and its role in gemcitabine sensitivity. Cancer research. 
2000;60(21):6075-6079. 
 
Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P. A new 
nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and 
resistant leukemia types. Journal of Controlled Release. 2007;124(1):20-27. 
 
Reddy LH, Ferreira H, Dubernet C, Mouelhi SL, Desmaele D, Rousseau B, Couvreur P. 
Squalenoyl nanomedicine of gemcitabine is more potent after oral administration 
in leukemia-bearing rats: study of mechanisms. Anticancer drugs. 
2008;19(10):999-1006. 
 
Reddy LH, Khoury H, Paci A, Deroussent A, Ferreira H, Dubernet C, Decleves X, Besnard 
M, Chacun H, Lepetre-Mouelhi S. Squalenoylation favorably modifies the in vivo 
pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metabolism 
and Disposition. 2008;36(8):1570-1577. 
 
Reddy LH, Marque PE, Dubernet C, Mouelhi SL, Desmaele D, Couvreur P. Preclinical 
toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine 
anticancer nanomedicine. J Pharmacol Exp Ther. 2008;325(2):484-490. 
 123 
 
Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 
London;Chicago;Washington, DC;: Pharmaceutical Press; 2009. 
 
Ruiz-Moreno C, Jimenez-Del-Rio M, Sierra-Garcia L, Lopez-Osorio B, Velez-Pardo C. 
Vitamin E synthetic derivate—TPGS—selectively induces apoptosis in jurkat t 
cells via oxidative stress signaling pathways: implications for acute lymphoblastic 
leukemia. Apoptosis. 2016;21(9):1019-1032. 
 
Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-
docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk 
factors. Am J Ther. 2009;16(2):183-192. 
 
Sandoval MA. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-
tumor activity. 2012;157(2):287-296. 
 
Sauer L, Dauchy R. The effect of omega-6 and omega-3 fatty acids on 3 H-thymidine 
incorporation in hepatoma 7288CTC perfused in situ. British journal of cancer. 
1992;66(2):297. 
 
Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese F. PEG–Ara-C conjugates 
for controlled release. European journal of medicinal chemistry. 2004;39(2):123-
133. 
 
Sebastiani V, Ricci F, Rubio-Viquiera B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru 
D, Iacobuzio-Donahue CA. Immunohistochemical and genetic evaluation of 
deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms 
of gemcitabine resistance and survival. Clinical Cancer Research. 
2006;12(8):2492-2497. 
 
Seeballuck F, Lawless E, Ashford MB, O’Driscoll CM. Stimulation of Triglyceride-Rich 
Lipoprotein Secretion by Polysorbate 80: In Vitro and in Vivo Correlation Using 




Serdjebi C, Milano G, Ciccolini J. Role of cytidine deaminase in toxicity and efficacy of 
nucleosidic analogs. Expert opinion on drug metabolism & toxicology. 
2015;11(5):665-672. 
 
Serini S, Piccioni E, Merendino N, Calviello G. Dietary polyunsaturated fatty acids as 
inducers of apoptosis: implications for cancer. Apoptosis. 2009;14(2):135-152. 
 
Serpe L, Catalano M, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, 
Gasco M, Eandi M. Cytotoxicity of anticancer drugs incorporated in solid lipid 
nanoparticles on HT-29 colorectal cancer cell line. European Journal of 
Pharmaceutics and Biopharmaceutics. 2004;58(3):673-680. 
 
Shimizu S. Routes of administration. The laboratory mouse. 2004:527-541. 
 
Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by 
protein antigens conjugated onto the surface of lecithin-based nanoparticles. 
Journal of Controlled Release. 2010;141(1):93-100. 
 
Sloat BR, Sandoval MA, Li D, Chung W-G, Lansakara-p DS, Proteau PJ, Kiguchi K, 
DiGiovanni J, Cui Z. In vitro and in vivo anti-tumor activities of a gemcitabine 
derivative carried by nanoparticles. International journal of pharmaceutics. 
2011;409(1):278-288. 
 
Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W, 
Dennison A. The effect of omega-3 FAs on tumour angiogenesis and their 
therapeutic potential. Eur J Cancer. 2009;45(12):2077-2086. 
 
Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I 
studies of gemcitabine. Semin Oncol. 1997;24(2 Suppl 7):S7-2-S7-7. 
 
Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty 
acid composition in relation to membrane fluidity and function. Biochimica et 
Biophysica Acta (BBA)-Reviews on Biomembranes. 1984;779(1):89-137. 
 
 125 
Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer 
targeted drug delivery. Pharmaceutical research. 2007;24(6):1029-1046. 
 
Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: 
challenges and opportunities. Journal of controlled release. 2013;170(1):15-40. 
Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC. Dietary 
supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte 
proliferation in healthy older humans. J Nutr. 2001;131(7):1918-1927. 
 
Thomson A, Keelan M, Garg M, Clandinin M. Intestinal aspects of lipid absorption: in 
review. Canadian journal of physiology and pharmacology. 1989;67(3):179-191. 
 
Tolis C, Peters G, Ferreira C, Pinedo H, Giaccone G. Cell cycle disturbances and apoptosis 
induced by topotecan and gemcitabine on human lung cancer cell lines. European 
journal of cancer. 1999;35(5):796-807. 
 
ud Din F, Mustapha O, Kim DW, Rashid R, Park JH, Choi JY, Ku SK, Yong CS, Kim JO, 
Choi H-G. Novel dual-reverse thermosensitive solid lipid nanoparticle-loaded 
hydrogel for rectal administration of flurbiprofen with improved bioavailability and 
reduced initial burst effect. European Journal of Pharmaceutics and 
Biopharmaceutics. 2015;94:64-72. 
 
Üner M, Wissing S, Yener G, Müller R. Solid lipid nanoparticles (SLN) and nanostructured 
lipid carriers (NLC) for application of ascorbyl palmitate. Die Pharmazie-An 
International Journal of Pharmaceutical Sciences. 2005;60(8):577-582. 
 
Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration 
routes and future perspectives. International journal of nanomedicine. 
2007;2(3):289. 
 
Valdes S, Alzhrani R, Andres R, S.P L-PD, G TS, Zhengrong C. A solid lipid nanoparticle 
formulation of 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine, a compound 
with potent, broad spectrum antitumor activity. In: Austin UoTa, editor.; 2018. 
 
 126 
Valdes S, Naguib YW, Finch RA, Baze WB, Jolly CA, Cui Z. Preclinical Evaluation of 
the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´-Difluorodeoxycytidine 
(DHA-dFdC). Pharmaceutical Research. 2017;34(6):1224-1232. 
 
Van Aken GA, Bomhof E, Zoet FD, Verbeek M, Oosterveld A. Differences in in vitro 
gastric behaviour between homogenized milk and emulsions stabilised by Tween 
80, whey protein, or whey protein and caseinate. Food Hydrocolloids. 
2011;25(4):781-788. 
 
Vandana M, Sahoo SK. Long circulation and cytotoxicity of PEGylated gemcitabine and 
its potential for the treatment of pancreatic cancer. Biomaterials. 
2010;31(35):9340-9356. 
 
Varshosaz J, Eskandari S, Tabbakhian M. Freeze-drying of nanostructure lipid carriers by 
different carbohydrate polymers used as cryoprotectants. Carbohydrate polymers. 
2012;88(4):1157-1163. 
 
Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-
Rhoades S, Andre VA, Beijnen JH, Slapak CA. Oral administration of gemcitabine 
in patients with refractory tumors: a clinical and pharmacologic study. Clinical 
Cancer Research. 2008;14(11):3477-3486. 
 
Vighi E, Ruozi B, Montanari M, Battini R, Leo E. Re-dispersible cationic solid lipid 
nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and 
ability to bind the pEGFP-plasmid. European Journal of Pharmaceutics and 
Biopharmaceutics. 2007;67(2):320-328. 
 
Wang C, Zheng Y, Sandoval MA, Valdes SA, Chen Z, Lansakara-P DS, Du M, Shi Y, Cui 
Z. Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse 
models. Oncotarget. 2017;8(52):89876-89886. 
 
Wang H, Xie H, Wu J, Wei X, Zhou L, Xu X, Zheng S. Structure-Based Rational Design 
of Prodrugs To Enable Their Combination with Polymeric Nanoparticle Delivery 




Wang J-X, Sun X, Zhang Z-R. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-
5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. European 
Journal of Pharmaceutics and Biopharmaceutics. 2002;54(3):285-290. 
 
Wang Y, Fan W, Dai X, Katragadda U, Mckinley D, Teng Q, Tan C. Enhanced tumor 
delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Molecular 
pharmaceutics. 2014;11(4):1140-1150. 
 
Wang Y, Li L, Jiang W, Yang Z, Zhang Z. Synthesis and preliminary antitumor activity 
evaluation of a DHA and doxorubicin conjugate. Bioorganic & Medicinal 
Chemistry Letters. 2006;16(11):2974-2977. 
 
Wickremsinhe E, Bao J, Smith R, Burton R, Dow S, Perkins E. Preclinical absorption, 
distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine 
designed to deliver prolonged systemic exposure. Pharmaceutics. 2013;5(2):261-
276. 
 
Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of 
polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 
2005;26(15):2713-2722. 
Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. 
Advanced drug delivery reviews. 2004;56(9):1257-1272. 
 
Wissing SA, Müller RH. Cosmetic applications for solid lipid nanoparticles (SLN). 
International Journal of Pharmaceutics. 2003;254(1):65-68. 
 
Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley 
MO, Anthony FH, Swindell CS, Witman PA. Phase I study of docosahexaenoic 
acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and 
toxicity profile. Clinical cancer research. 2003;9(10):3589-3597. 
 
Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics 
of gemcitabine. Drug Metab Rev. 2009;41(2):77-88. 
 
 128 
Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs 
encapsulated in solid lipid nanoparticles. Advanced drug delivery reviews. 
2007;59(6):491-504. 
 
Wu S-W, Hopkins WK. Characteristics of d-α-tocopheryl PEG 1000 succinate for 
applications as an absorption enhancer in drug delivery systems. Pharmaceutical 
technology. 1999;23(10):52-68. 
 
Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, Slapak CA, 
Benhadji KA, Tamura T. Phase I study of oral gemcitabine prodrug (LY2334737) 
in Japanese patients with advanced solid tumors. Cancer chemotherapy and 
pharmacology. 2013;71(6):1645-1655. 
 
Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid 
nanoparticles after oral administration. Pharmaceutical research. 1999;16(5):751-
757. 
 
Yardley DA. Gemcitabine plus paclitaxel in breast cancer. Semin Oncol. 2005;32(4 Suppl 
6):S14-21. 
 
Yi J, Lam TI, Yokoyama W, Cheng LW, Zhong F. Cellular uptake of β-carotene from 
protein stabilized solid lipid nanoparticles prepared by homogenization–
evaporation method. Journal of agricultural and food chemistry. 2014;62(5):1096-
1104. 
 
Youk H-J, Lee E, Choi M-K, Lee Y-J, Chung JH, Kim S-H, Lee C-H, Lim S-J. Enhanced 
anticancer efficacy of α-tocopheryl succinate by conjugation with polyethylene 
glycol. Journal of controlled release. 2005;107(1):43-52. 
 
Yu P, Yu H, Guo C, Cui Z, Chen X, Yin Q, Zhang P, Yang X, Cui H, Li Y. Reversal of 
doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive 
micelles. Acta biomaterialia. 2015;14:115-124. 
 
Yuan H, Chen C-Y, Chai G-h, Du Y-Z, Hu F-Q. Improved transport and absorption through 




Yuan Q, Han J, Cong W, Ge Y, Ma D, Dai Z, Li Y, Bi X. Docetaxel-loaded solid lipid 
nanoparticles suppress breast cancer cells growth with reduced myelosuppression 
toxicity. International journal of nanomedicine. 2014;9:4829. 
Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and 
pharmacodynamic data analysis in Microsoft Excel. Computer methods and 
programs in biomedicine. 2010;99(3):306-314. 
 
Zhang Z, Tan S, Feng S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. 
Biomaterials. 2012;33(19):4889-4906. 
 
Zhao L, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-
TPGS emulsified nanoparticles of biodegradable polymers: In vitro and in vivo 
studies. Journal of pharmaceutical sciences. 2010;99(8):3552-3560. 
 
Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3 polyunsaturated 
fatty acids and risk of breast cancer: meta-analysis of data from 21 independent 
prospective cohort studies. Bmj. 2013;346:f3706. 
 
Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y, Gao Y, Zhang J, Liu K, Liu R. Co-
delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA 
nanoparticles for enhanced chemotherapy against multi-drug resistance. 
Biomaterials. 2014;35(7):2391-2400. 
 
Zhu S, Lansakara-P DS, Li X, Cui Z. Lysosomal delivery of a lipophilic gemcitabine 
prodrug using novel acid-sensitive micelles improved its antitumor activity. 
Bioconjugate chemistry. 2012;23(5):966-980. 
 
Zhu S, Li X, Lansakara PD, Kumar A, Cui Z. A nanoparticle depot formulation of 4-(N)-
stearoyl gemcitabine shows a strong antitumor activity. The Journal of pharmacy 
and pharmacology. 2013;65(2):236-242. 
 
Zhu S, Wonganan P, Lansakara-P DSP, O'Mary HL, Li Y, Cui Z. The effect of the acid-
sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused 
by RRM1 overexpression. Biomaterials. 2013;34(9):2327-2339. 
 
 130 
Zur Mühlen A, Mehnert W. Drug release and release mechanism of prednisolone loaded 
solid lipid nanoparticles. Pharmazie. 1998;53(8):552-555. 
 
Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new 






Solange Alondra Valdes Curiquen was born in Santiago, Chile in 1980. She received a 
Bachelor’s degree of Biochemistry in 2009 from the University of Chile. She joined the Graduate 
School at the University of Texas at Austin in Fall 2013. During this time, she worked as graduate 
research assistant in Cui’ Lab as well as teaching assistant at the college of Natural Science at the 




Permanent e-mail: solvaldes@gmail.com 
This dissertation was typed by the author. 
 
 
 
 
